Preparation method and application of exogenous gene independent porcine induced pluripotent stem cells
Through specific signaling pathways and non-integrated vector systems, the problem of insufficient stability and long-term cultivation capabilities of pig iPSCs in the prior art is solved, and the production of high-quality, foreign gene-free pig iPSCs is achieved, which is suitable for a variety of Application field.
Patent Information
- Application Number
- CN202410546534.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-06
- Filing Date
- 2024-05-06
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to establish high-quality, foreign genetic modification-free pig induced pluripotent stem cell (iPSCs) systems, especially in maintaining a stable pluripotent state and long-term cultivation capabilities.
By analyzing the critical signaling pathways that do not rely on porposite stem cells, a reprogramming culture system is provided that uses WNT signaling pathway inhibitors, CHIR99021, Src inhibitors, LIF and TGF-β supers Factors such as family members, combined with non-integrated vector systems, realize the generation of pig iPSCs without genetic modification.
Successfully obtained stable genetically modified pig iPSCs with long-term cultivation and self-renewal ability, with good pluripotency characteristics and three-germ layer differentiation ability, suitable for preclinical evaluation, germplasm resource preservation, and biocultural meat preparation. field.
Smart Images

Figure CN118909950A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for preparing porcine induced pluripotent stem cells. The method can produce stable, non-genetically modified porcine induced pluripotent stem cells with long-term culture and self-renewal capabilities from porcine somatic cells, and has application potential in many fields such as preclinical evaluation, germplasm resource preservation, new variety breeding, and preparation of biological cultured meat products. Background Art
[0002] Reprogramming somatic cells into induced pluripotent stem cells (iPSCs) makes autologous treatment possible, and because it does not have ethical issues, it has greater application value in translational medicine. Compared with mice, pigs and humans have more similarities in physiology and anatomy; compared with monkeys, pigs are cheaper and have no ethical issues. This makes pig iPSCs an ideal model for preclinical evaluation of human iPSCs. Pigs are also important livestock animals. In the field of endangered pig germplasm resource conservation, iPSCs are easy to obtain and have greater advantages than establishing embryonic stem cells. In addition, because stem cells have unlimited proliferation ability, pig iPSCs have greater advantages than fibroblasts in the preparation of complex gene editing models or pig breed breeding, and pig iPSCs can be used as good seed cells for cultivating cell meat products. However, since the establishment of the porcine iPSCs induction system in 2009, due to the insufficient understanding of the regulation mechanism of porcine pluripotency and the lack of a suitable culture system, efficient reprogramming and the establishment of transgene-independent porcine iPSCs with stable pluripotency state remain unresolved problems.
[0003] In order to solve the above problems, a Chinese patent with publication number CN113966393A discloses a culture medium for establishing a mammalian expansion potential stem cell line. The system supports the use of an integrated plasmid that induces the expression of exogenous genes to induce pig fibroblasts into pluripotent stem cells. The established pig iPSCs can be independent of exogenous reprogramming factors, but exogenous genes are still integrated in their genome. Recently, a Chinese patent with publication number CN115702241A also invented an iPSC induction patent, which provides a method for inducing pluripotency in livestock neural stem cells or fibroblasts using a non-integrated Sendai virus that expresses one or more reprogramming factors. Using this method, iPSCs with partial pluripotency characteristics derived from pig neural stem cells can be obtained, but iPSCs cannot be obtained from fibroblasts.
[0004] In short, there is currently no high-quality, non-exogenous gene-modified pig iPSCs induction system at home and abroad. Summary of the invention
[0005] The inventors of the present application have analyzed the key signaling pathways for establishing exogenous gene-independent induced pluripotent stem cells specific to pigs, and provided a reprogramming culture system that can generate stable, long-term culture and self-renewal-capable, non-genetically modified pig induced pluripotent stem cells from pig somatic cells. The following invention is provided.
[0006] Reprogramming culture system
[0007] In a first aspect, the present invention provides a method for producing induced pluripotent stem cells (iPSCs), the method comprising:
[0008] (i) Reprogramming pig somatic cells;
[0009] (ii) culturing the cells of step (i) in a medium comprising a WNT signaling pathway inhibitor, CHIR99021, a Src inhibitor, LIF, a TGF-β superfamily member, and a fibroblast growth factor to generate iPSCs.
[0010] Training system
[0011] In certain embodiments, the WNT signaling pathway inhibitor is IWR-1.
[0012] In certain embodiments, the Src inhibitor is WH-4-023.
[0013] In certain embodiments, the TGF-β superfamily member is Activin A, such as human Activin A.
[0014] In certain embodiments, the fibroblast growth factor is FGF2, such as human FGF2.
[0015] In certain embodiments, the LIF is human LIF.
[0016] In certain embodiments, the WNT signaling pathway inhibitor is IWR-1, and the content ratio of IWR-1 to CHIR99021 is 2:3-1:3, such as 1:2-1:3.
[0017] In certain embodiments, the content ratio of the WNT signaling pathway inhibitor to CHIR99021 is 25: 1-1: 25, such as 25: 1, 20: 1, 15: 1, 10: 1, 5: 1, 4: 1, 3: 1, 2: 1, 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 15, 1: 20 or 1: 25. In certain embodiments, the content ratio of the WNT signaling pathway inhibitor to CHIR99021 is 2: 3-1: 3, such as 1: 2-1: 3.
[0018] In certain embodiments, the concentration of the WNT signaling pathway inhibitor is 1-5 μM, such as 1 μM, 2.5 μM, 3 μM, 5 μM.
[0019] In some embodiments, the concentration of the WNT signaling pathway inhibitor is 2 to 3 μM. In some embodiments, the concentration of the WNT signaling pathway inhibitor is 2.5 μM.
[0020] In certain embodiments, the concentration of CHIR99021 is 0.01-3 μM, such as 0.01 μM, 0.1 μM, 1 μM, 2 μM, 3 μM.
[0021] In certain embodiments, the concentration of CHIR99021 is 0.5-2 μM, 0.5-1.5 μM, 0.5-1 μM or 1-2 μM. In certain embodiments, the concentration of CHIR99021 is 1 μM.
[0022] In certain embodiments, the concentration of the Src inhibitor is 0.01-5 μM, such as 0.01 μM, 0.1 μM, 1 μM, 3 μM, 5 μM.
[0023] In certain embodiments, the concentration of the Src inhibitor is 0.5-2 μM, 0.5-1.5 μM, 0.5-1 μM or 1-2 μM. In certain embodiments, the concentration of the Src inhibitor is 1 μM.
[0024] In certain embodiments, the concentration of LIF is 1-100 ng / mL, such as 1 ng / mL, 10 ng / mL, 25 ng / mL, 50 ng / mL, 100 ng / mL.
[0025] In certain embodiments, the concentration of LIF is 5-20 ng / mL, 5-15 ng / mL, 8-12 ng / mL, 5-10 ng / mL, 10-20 ng / mL. In certain embodiments, the concentration of LIF is 10 ng / mL.
[0026] In certain embodiments, the concentration of the TGF-β superfamily member is 1-100 ng / mL, such as 1 ng / mL, 10 ng / mL, 25 ng / mL, 50 ng / mL, 100 ng / mL.
[0027] In certain embodiments, the concentration of the TGF-β superfamily member is 10-30 ng / mL, 20-30 ng / mL, 20-25 ng / mL, 25-30 ng / mL. In certain embodiments, the concentration of the TGF-β superfamily member is 25 ng / mL.
[0028] In certain embodiments, the concentration of the fibroblast growth factor is 1-100 ng / mL, such as 1 ng / mL, 10 ng / mL, 25 ng / mL, 50 ng / mL, 100 ng / mL.
[0029] In certain embodiments, the concentration of the fibroblast growth factor is 5-20 ng / mL, 5-15 ng / mL, 8-12 ng / mL, 5-10 ng / mL, 10-20 ng / mL. In certain embodiments, the concentration of the fibroblast growth factor is 10 ng / mL.
[0030] In certain preferred embodiments, the culture medium comprises: 1-5 μM WNT signaling pathway inhibitor (e.g., IWR-1), 0.01-3 μM CHIR99021, 0.01-5 μM Src inhibitor (e.g., WH-4-023), 1-100 ng / mL TGF-β superfamily member (e.g., Activin A, such as human Activin A), 1-100 ng / mL fibroblast growth factor (e.g., FGF2, human FGF2) and 1-100 ng / mL LIF (e.g., human LIF).
[0031] In certain exemplary embodiments, the culture medium comprises: 2-3 μM WNT signaling pathway inhibitor (e.g., IWR-1), 0.5-2 μM CHIR99021, 0.5-2 μM Src inhibitor (e.g., WH-4-023), 10-30 ng / mL TGF-β superfamily member (e.g., Activin A, such as human Activin A), 5-20 ng / mL fibroblast growth factor (e.g., FGF2, human FGF2), and 5-20 ng / mL LIF (e.g., human LIF).
[0032] In certain exemplary embodiments, the culture medium comprises: 2.5 μM WNT signaling pathway inhibitor (e.g., IWR-1), 1 μM CHIR99021, 1 μM Src inhibitor (e.g., WH-4-023), 25 ng / mL TGF-β superfamily member (e.g., Activin A, such as human Activin A), 10 ng / mL fibroblast growth factor (e.g., FGF2, human FGF2), and 10 ng / mL LIF (e.g., human LIF).
[0033] In certain exemplary embodiments, the culture medium comprises: 2.5 μM IWR-1, 1 μM CHIR99021, 1 μM WH-4-023, 25 ng / mL Activin A (eg, human Activin A), 10 ng / mL FGF2 (eg, human FGF2), and 10 ng / mL LIF (eg, human LIF).
[0034] It should be noted that the concentrations of the above components refer to the final concentrations of the components in the culture medium.
[0035] In certain embodiments, the culture medium of step (ii) further comprises a basal medium.
[0036] In certain embodiments, the basal medium is a basal medium for culturing mammalian (preferably porcine) pluripotent stem cells.
[0037] In certain embodiments, the base medium comprises a minimal medium, an N2 supplement, a B27 supplement, non-essential amino acids, β-mercaptoethanol, a serum replacement (eg, a knockout serum replacement), and glutamine or a derivative thereof (eg, GlutaMAX).
[0038] In certain embodiments, the base medium comprises basal medium, N2 supplement, B27 supplement, non-essential amino acids, β-mercaptoethanol, serum replacement (eg, knockout serum replacement), and GlutaMAX.
[0039] In certain embodiments, the basal medium further comprises ascorbic acid.
[0040] In certain embodiments, the basal medium further comprises penicillin-streptomycin.
[0041] In certain embodiments, the basic culture medium is selected from DMEM / F12, Neurobasal, DMEM, KO-DMEM, RPMI1640, MEM, mTeSR1, or any combination thereof.
[0042] In certain embodiments, the basic culture medium is selected from DMEM / F12, Neurobasal, or a combination thereof.
[0043] In certain embodiments, the basic culture medium is DMEM / F12 and Neurobasal.
[0044] In certain embodiments, the volume fraction of the N2 supplement is 0.002%-10%, for example 0.1%-10%, such as 0.1%-5%, such as 0.1%-2%, such as 0.1%-1%, such as 0.5%-2%, such as 0.5%-1%, such as 0.2%-2%, such as 0.2%-1%, preferably 0.5%.
[0045] In certain embodiments, the volume fraction of the B27 supplement is 0.002%-20%, such as 0.1%-20%, such as 0.1%-10%, such as 0.1%-5%, such as 0.1%-2%, such as 0.5%-5%, such as 0.5%-2%, such as 1%-5%, such as 1%-2%, preferably 1%.
[0046] In certain embodiments, the volume fraction of the non-essential amino acids is 0.01%-10%, for example 0.1%-20%, such as 0.1%-10%, such as 0.1%-5%, such as 0.1%-2%, such as 0.5%-5%, such as 0.5%-2%, such as 1%-5%, such as 1%-2%, preferably 1%.
[0047] In certain embodiments, the concentration of β-mercaptoethanol is 0.01%-1%, such as 0.05%-1%, such as 0.08%-1%, such as 0.1%-1%, such as 0.05%-0.5%, such as 0.08%-0.5%, such as 0.1%-0.5%, preferably 0.1%.
[0048] In certain embodiments, the volume fraction of the serum substitute (eg, knockout serum replacement) is 0.01%-50%, such as 1-50%, 1-30%, 1-20%, 2-30%, 2-20%, 5-20%, preferably 5%.
[0049] In certain embodiments, the concentration of ascorbic acid is 1 μg / mL-5000 μg / mL, for example, 1 μg / mL-100 μg / mL, 10 μg / mL-100 μg / mL, 20 μg / mL-100 μg / mL, 20 μg / mL-80 μg / mL, 30 μg / mL-80 μg / mL, 30 μg / mL-60 μg / mL, 40 μg / mL-60 μg / mL, and preferably 50 μg / mL.
[0050] In certain embodiments, the volume fraction of glutamine or its derivative (e.g., GlutaMAX) is 0.01%-10%, for example, 0.1%-10%, such as 0.1%-5%, such as 0.1%-2%, such as 0.1%-1%, such as 0.5%-2%, such as 0.5%-1%, such as 0.2%-2%, such as 0.2%-1%, and preferably 0.5%.
[0051] In certain embodiments, the volume fraction of penicillin-streptomycin is 0.01%-20%, for example 0.1%-20%, such as 0.1%-10%, such as 0.1%-5%, such as 0.1%-2%, such as 0.5%-5%, such as 0.5%-2%, such as 1%-5%, such as 1%-2%, preferably 1%.
[0052] In certain embodiments, the volume ratio of the DMEM / F12 to the Neurobasal is 5:1-1:5, such as 2:1-1:2, preferably 1:1.
[0053] In certain embodiments, the volume fraction of the basic culture medium is 1%-99%, such as 50%-99%, 60%-99%, 50%-95%, 60%-95%, 80%-95%, 85%-95%, 90%-95%, preferably 91%.
[0054] In certain embodiments, the volume fraction of DMEM / F12 is 1%-99%, such as 40%-60%, 40%-50%, preferably 45%-50% (such as 45.5%).
[0055] In certain embodiments, the volume fraction of Neurobasal is 1%-99%, such as 40%-60%, 40%-50%, and preferably 45%-50% (such as 45.5%).
[0056] In certain exemplary embodiments, the basal medium is a basal medium (e.g., DMEM / F12 / Neurobasal in a volume ratio of 2:1-1:2, preferably 1:1) supplemented with the following components: 0.1%-5% (e.g., 0.1%-2%, 0.1%-1%, 0.5%-2%, 0.5%-1%, 0.2%-2%, 0.2%-1%) N2 supplement, 0.1%-5% (e.g., 0.1%-2%, 0.5%-5%, 0.5%-2%, 1%-5%, 1%-2%) B27 supplement. supplement, 0.1%-5% (such as 0.1%-2%, 0.5%-5%, 0.5%-2%, 1%-5%, 1%-2%) non-essential amino acids, 0.1%-1% (0.05%-0.5%, such as 0.08%-0.5%, 0.1%-0.5%) β-mercaptoethanol, 1-30% (such as 1-20%, 2-30%, 2-20%, 5-20%) serum replacement, and 0.1%-5% (such as 0.1%-2%, 0.1%-1%, 0.5%-2%, 0.5%-1%, 0.2%-2%, 0.2%-1%) glutamine or its derivatives. Preferably, it further comprises 20 μg / mL-80 μg / mL (such as 30 μg / mL-80 μg / mL, 30 μg / mL-60 μg / mL, 40 μg / mL-60 μg / mL) ascorbic acid. Preferably, it further comprises 0.1%-5% (such as 0.1%-2%, 0.5%-5%, 0.5%-2%, 1%-5%, 1%-2%) penicillin-streptomycin.
[0057] In certain exemplary embodiments, the basal medium is a minimal medium supplemented with the following components (e.g., DMEM / F12 / Neurobasal in a volume ratio of 2:1-1:2, preferably 1:1): 0.5% N2supplement, 1% B27supplement, 1% non-essential amino acids, 0.1% β-mercaptoethanol, 5% serum replacement, 0.5% glutamine or its derivatives, and 50 μg / mL ascorbic acid.
[0058] It should be noted that the concentration of each specific component in the above-mentioned basal culture medium refers to the final concentration of each specific component in the culture medium, and the volume fraction of each specific component refers to the volume of the specific component / total volume of the culture medium.
[0059] In certain embodiments, the culture after the reprogramming factors are introduced into the somatic cells is carried out in the presence of a feeder layer. In certain embodiments, the feeder layer is mouse embryonic fibroblasts.
[0060] In certain embodiments, the method further comprises a passaging step.
[0061] In certain embodiments, the culture medium used in the subculturing step is the culture medium described in step (ii).
[0062] In certain embodiments, the culture medium used in the subculturing step is the culture medium in step (ii) after adding a ROCK inhibitor. In certain embodiments, the ROCK inhibitor is Y-27632. In certain embodiments, the content of the ROCK inhibitor is 0.01-50 μM, such as 0.01-20 μM, 0.1-20 μM, 0.1-10 μM, 0.1-5 μM, 0.5-5 μM, 1-5 μM, such as 2 μM.
[0063] Reprogramming
[0064] Reprogramming of somatic cells can be performed using any method known in the art. Typically, somatic cell pluripotency reprogramming technology can convert differentiated somatic cells into induced pluripotent stem cells (iPSCs) by using reprogramming transcription factors (such as OCT4, SOX2, KLF4, C-MYC).
[0065] In certain embodiments, the reprogramming comprises: introducing reprogramming factors into pig somatic cells. In certain embodiments, the somatic cells are fibroblasts (e.g., embryonic fibroblasts or adult fibroblasts), mesenchymal cells, perivascular cells, renal epithelial cells in urine, and peripheral blood mononuclear cells.
[0066] In certain embodiments, the reprogramming factors include OCT4, SOX2, KLF4 and C-MYC. Preferably, the reprogramming factors include hOCT4, hSOX2, hKLF4, hC-MYC.
[0067] In certain embodiments, the reprogramming factors further include BCL2L1. Preferably, the reprogramming factors include hBCL2L1.
[0068] In certain embodiments, the reprogramming factors include hOCT4, hSOX2, hKLF4, hC-MYC, and hBCL2L1.
[0069] In certain embodiments, for more differentiated somatic cells (e.g., adult fibroblasts), the reprogramming factors may further include LIN28A and NANOG. In certain embodiments, preferably, the LIN28A and NANOG are derived from pigs, so the reprogramming factors also include pLIN28A and pNANOG.
[0070] In certain embodiments, the reprogramming factors include hOCT4, hSOX2, hKLF4, hC-MYC, hBCL2L1, pLIN28A, and pNANOG.
[0071] In certain embodiments, the reprogramming factors are encoded by one or more exogenous expression cassettes.
[0072] In certain embodiments, the nucleotide sequence encoding each of the reprogramming factors is optionally located in the same or different expression cassettes. For example, nucleic acid molecules encoding OCT4 and hSOX2 can be located in the same expression cassette, and nucleic acid molecules encoding other factors are located in different expression cassettes.
[0073] In certain embodiments, the introduction of the reprogramming factors is achieved in a non-integrating form.
[0074] In certain embodiments, the one or more exogenous expression cassettes are contained in a non-integrating vector.
[0075] In certain embodiments, the non-integrating vector is introduced into the cell by electrofection.
[0076] In certain embodiments, the non-integrating vector is an Episomal vector. Typically, prolonged expression of reprogramming factors can be achieved by episomal vectors based on oriP / EBNA1. These plasmids contain oriP / EBNA1 viral elements derived from Epstein-Barr virus, which promote the replication of free plasmid DNA in dividing cells, thereby allowing the reprogramming factors to be expressed long enough to initiate the reprogramming process, and the plasmid will eventually be lost from the proliferating cells, leaving no trace of plasmid transfection.
[0077] In certain embodiments, the non-integrating vector is a pEV vector comprising a spleen focus forming virus promoter (SFFV), WPRE, OriP, and EBNA1 elements.
[0078] In certain embodiments, the method further comprises: (iii) detecting the residual state of the exogenous gene at the endogenous locus to screen cells without the residual exogenous gene at the endogenous locus, thereby obtaining pig iPSCs without exogenous gene modification.
[0079] In certain embodiments, the introduction of the reprogramming factors is achieved in an integrated form.
[0080] In certain embodiments, the one or more exogenous expression cassettes are contained in an integrative vector.
[0081] In certain embodiments, the integrative vector is introduced into the cell by viral transfection.
[0082] In certain embodiments, the integrating vector is a retroviral, lentiviral, or transposase vector.
[0083] In certain embodiments, the method further comprises: (iii) detecting (e.g., quantitative PCR or semi-quantitative PCR) the expression of the exogenous gene to screen for cells in which the exogenous gene is silenced, thereby obtaining exogenous gene-silenced pig iPSCs.
[0084] In certain embodiments, the reprogramming step is performed in a culture medium, which is any culture medium suitable for somatic cells. For example, for fibroblasts, the culture medium can be a basic culture medium (e.g., DMEM) supplemented with serum (e.g., FBS); preferably, the culture medium is also supplemented with non-essential amino acids (e.g., NEAA); preferably, the culture medium contains 5-20% serum (e.g., 5-15%, 10-20%, 10-15%; e.g., 5%, 8%, 10%, 12% or 15%) and 0.01%-10% non-essential amino acids (e.g., 1-10%, 1-5%, 1-2%, 1%); preferably, the culture medium also contains penicillin-streptomycin; for example, the volume fraction is 0.01%-20%, preferably 1%.
[0085] In certain embodiments, the method comprises: introducing the reprogramming factors into somatic cells, pre-culturing in a culture medium suitable for the somatic cells, and then gradually replacing the pre-culture medium with the culture medium described in step (ii).
[0086] Identification
[0087] The pluripotent stem cells generated by the methods described herein can be identified in a variety of ways.
[0088] In some embodiments, the expression of pluripotency genes is detected by qPCR and immunofluorescence staining. The results show that the iPSC expresses pluripotency marker genes. In some embodiments, the method produces cells expressing OCT4, SOX2, and NANOG. In some embodiments, the cells also express KLF4, C-MYC, REX1, LIN28A, SALL4, and OTX2.
[0089] In certain embodiments, the genome stability of high-passage iPSCs is analyzed from the perspectives of karyotype, degree of DNA damage, and damage repair, etc. The results show that high-passage iPSCs can maintain genome stability.
[0090] In certain embodiments, teratoma formation and three germ layer differentiation are detected. The results show that the iPSC can form teratomas in nude mice, and the formed teratomas can differentiate into tissues including neural ectoderm, muscle mesoderm, intestinal epithelial endoderm, etc.
[0091] In certain embodiments, the methylation degree of the pluripotency gene promoter is detected. The results show that the OCT4 and NANOG promoters of the iPSC are in a low methylation state.
[0092] In certain embodiments, the transgenic ability is tested and the results show that the iPSCs have transgenic ability.
[0093] In certain embodiments, the pluripotency characteristics are detected. The results show that at the transcriptome level, the iPSC has similar characteristics to pgEpiSC, close to the embryonic epiblast stem cells at the E10 stage of embryonic development. pgEpiSC refers to pig pregastrulation epiblast pluripotent stem cells, see Zhi, M., Zhang, J., Tang, Q. et al. Generation and characterization of stable pig pregastrulation epiblast stem cell lines. Cell Res 32, 383-400 (2022).
[0094] In certain embodiments, the developmental capacity of cloned embryos derived from the iPSCs is tested. The results show that cloned embryos generated by using fibroblast-like cells differentiated from the iPSCs as donor cells for cloning can develop to the blastocyst stage, and the blastocyst development rate is about 20%, which has the potential to be used as donor cells for nuclear transplantation.
[0095] In a second aspect, the present invention relates to use of the culture medium described in the first aspect for preparing induced pluripotent stem cells (iPSCs). Preferably, the iPSCs are exogenous gene-independent porcine iPSCs.
[0096] Exogenous gene-independent porcine iPSCs
[0097] In a third aspect, the present invention relates to induced pluripotent stem cells (iPSCs) produced by the method of the first aspect.
[0098] In certain embodiments, the iPSC expresses OCT4, SOX2, NANOG. Preferably, the iPSC also expresses KLF4, C-MYC, REX1, LIN28A, SALL4 and OTX2.
[0099] In certain embodiments, the iPSCs are downregulated, for example, at least 4-fold reduced, in the expression level of at least 1 (e.g., at least 2, at least 5, or all 10) gene selected from the following: NR4A1, NR4A2, NR4A3, FOSB, CCN2, CCN1, THBS1, RPL26, EGR4, and DUSP2, compared to porcine pre-gastrulation epiblast pluripotent stem cells (pgEpiSCs).
[0100] In certain embodiments, the iPSCs have upregulated expression levels of at least one (e.g., at least two, at least five, or all six) gene selected from the following, such as at least a 6-fold increase, compared to porcine pre-gastrulation epiblast pluripotent stem cells (pgEpiSCs): FABP3, FN3KRP, DNPH1, ANXA1, RUSC1, SNX1.
[0101] In certain embodiments, the iPSCs have the ability to differentiate into cells of any one of endoderm, ectoderm, and mesoderm.
[0102] In certain embodiments, the iPSCs are capable of forming a domed shape clone morphology.
[0103] In certain embodiments, the iPSCs are capable of stable passage at least 50 times or more. Preferably, the iPSCs are capable of stable passage at least 100 times or more.
[0104] In certain embodiments, the iPSCs are exogenous gene-independent porcine iPSCs.
[0105] application
[0106] In a fourth aspect, the present invention relates to genetically modified iPSCs, which are obtained by genetically modifying the iPSCs described in the third aspect.
[0107] In certain embodiments, the genetic modification comprises genome editing, for example comprising nucleic acid fragment deletion, gene modification, gene knockout, altered expression of gene products, repair of mutations, insertion of polynucleotides, single base mutations or any combination thereof.
[0108] In certain embodiments, the genome editing comprises gene insertion, gene knock-in, gene knock-out, gene mutation (eg, single base mutation), or any combination thereof.
[0109] In a fifth aspect, the present invention relates to a method for producing cells, tissues or organs (e.g., organoids) in vitro, comprising: culturing the iPSC described in the third aspect or the genetically modified iPSC described in the fourth aspect under conditions of inducing differentiation. It also relates to the use of the iPSC described in the third aspect or the genetically modified iPSC described in the fourth aspect for producing cells, tissues or organs (e.g., organoids) in vitro.
[0110] In certain embodiments, the cell comprises a cell of the endoderm, ectoderm, or mesoderm.
[0111] In certain embodiments, the cell is selected from the group consisting of an immune cell, a dopaminergic neural precursor cell, a cardiomyocyte, a beta cell, an eye-specific cell, a muscle cell, a fat cell, and a bone cell.
[0112] In certain embodiments, the organoid is selected from intestinal organoids, kidney organoids, liver organoids, brain organoids, alveolar organoids, gastric organoids, and the like.
[0113] In certain embodiments, the method further comprises generating iPSCs using the method described in the first aspect, and subsequently using the iPSCs to generate cells, tissues or organs (eg, organoids) in vitro.
[0114] In a sixth aspect, the present invention relates to a method for preparing cultured meat, comprising: (1) providing the iPSC described in the third aspect or the genetically modified iPSC described in the fourth aspect; (2) inducing the iPSC described in step (1) to differentiate into muscle cells to obtain cultured meat. It also relates to the use of the iPSC described in the third aspect or the genetically modified iPSC described in the fourth aspect for preparing cultured meat; preferably, the iPSC or the genetically modified iPSC is used as a seed cell.
[0115] In certain embodiments, the method further comprises generating iPSCs using the method described in the first aspect, and subsequently using the iPSCs to prepare cultured meat.
[0116] In a seventh aspect, the present invention relates to a method for producing pig embryos, the method comprising: establishing an embryo by a nuclear transplantation process, wherein the nucleus of the iPSC described in the third aspect or the genetically modified iPSC described in the fourth aspect is transplanted into an enucleated pig oocyte or egg cell. It also relates to the use of the iPSC described in the third aspect or the genetically modified iPSC described in the fourth aspect for producing pig embryos.
[0117] In certain embodiments, prior to performing the nuclear transplantation, the method further comprises culturing the nuclear donor cell under conditions that induce differentiation.
[0118] In certain embodiments, the method comprises forming fibroblasts as nuclear donor cells under differentiation-inducing conditions of FGF2, BMP4, and SB431542.
[0119] In certain embodiments, the method comprises: generating the iPSC from pig somatic cells using the method described in the first aspect, or generating iPSC from pig somatic cells using the method described in the first aspect and genetically modifying the iPSC to generate the genetically modified iPSC.
[0120] In certain embodiments, the iPSCs or genetically modified iPSCs are derived from somatic cells of a rare or endangered pig species.
[0121] In an eighth aspect, the present invention relates to use of an agent capable of inhibiting the WNT signaling pathway for preparing exogenous gene-independent pig iPSCs.
[0122] In certain embodiments, the agent comprises a WNT signaling pathway inhibitor and CHIR99021.
[0123] In certain embodiments, the WNT signaling pathway inhibitor is IWR-1.
[0124] In certain embodiments, the agent comprises IWR-1 and CHIR99021.
[0125] In certain embodiments, the WNT signaling pathway inhibitor is IWR-1, and the content ratio of IWR-1 to CHIR99021 is 2:3-1:3, such as 1:2-1:3.
[0126] In certain embodiments, the content ratio of the WNT signaling pathway inhibitor to CHIR99021 is 25: 1-1: 25, such as 25: 1, 20: 1, 15: 1, 10: 1, 5: 1, 4: 1, 3: 1, 2: 1, 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 15, 1: 20 or 1: 25. In certain embodiments, the content ratio of the WNT signaling pathway inhibitor to CHIR99021 is 2: 3-1: 3, such as 1: 2-1: 3.
[0127] In a ninth aspect, the present invention relates to use of LIF for improving the reprogramming efficiency of exogenous gene-independent porcine iPSCs.
[0128] In a tenth aspect, the present invention relates to use of a SRC inhibitor for maintaining the dome-shaped clonal morphology of exogenous gene-independent porcine iPSCs.
[0129] Advantageous Effects of the Invention
[0130] The present invention provides for the first time a method and a reprogramming system for generating stable, non-genetically modified pig induced pluripotent stem cells from pig somatic cells that have the ability to be cultured for a long time and self-renew. The pig iPSCs thus obtained have good pluripotency characteristics, can differentiate into tissues derived from the three germ layers in vivo and in vitro, and can be used as donor cells for nuclear transplantation. Among them, the induced pluripotent stem cells obtained by the non-integrating vector system have no exogenous vector fragment integration and have greater application value.
[0131] Embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings and examples, but it will be appreciated by those skilled in the art that the following drawings and examples are only used to illustrate the present invention, rather than to limit the scope of the present invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the accompanying drawings and preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0132] Figure 1 The reprogramming system of the present invention is used to establish exogenous gene-silenced induced pluripotent stem cells from pig ear fibroblasts.
[0133] Figure 1A is a reprogramming flow chart. One day before viral infection, adult fibroblasts (GNT-pEFs) carrying GFP random insertion, NANOG-tdTomato knock in, and TYR+ / - were passaged. Three days after viral infection, the virus-infected fibroblasts were inoculated into wells with feeder cells and replaced with the 3i / LAF induction system the next day. When clones with good morphology were generated, they were picked up with a mouth pipette for clone expansion and culture.
[0134] Figure 1B shows the cell status and fluorescence images recorded on the 7th and 16th days of reprogramming (scale bar: 100 μm).
[0135] Figure 1C shows the cell status and AP staining of the established GNT-iPSCs (scale bar: 200 μm).
[0136] Figure 1D shows the uniform NANOG-tdTomato fluorescence presented by GNT-iPSCs (scale bar: 100 μm).
[0137] Figure 1E shows that the expression of exogenous genes in 5 randomly selected GNT-iPSCs was significantly reduced.
[0138] Figure 1F shows immunofluorescence staining of pluripotency genes in GNT-iPSCs#9 (scale bar: 50 μm).
[0139] Figure 2 The present invention is a process of inducing embryonic fibroblasts to be reprogrammed into iPSCs using the retroviral reprogramming system of the present invention.
[0140] Figure 2A is a diagram of the cell status during the reprogramming process.
[0141] Figure 2B shows the status of pMX-iPSCs and AP staining (scale bar: 100 μm).
[0142] Figure 2C is a statistical diagram of the induction efficiency of pMX-iPSCs (scale bar: 100 μm).
[0143] Figure 2D shows the detection of exogenous gene expression in pMX-iPSCs.
[0144] Figure 2E shows the detection of genome integration of exogenous vector fragments in pMX-iPSCs.
[0145] Figure 2F shows the expression of pluripotency genes in pMX-iPSCs detected by qPCR.
[0146] Figure 2G shows the expression of pluripotency genes in pMX-iPSCs detected by immunofluorescence (scale bar: 50 μm).
[0147] Figure 3 The process of inducing embryonic fibroblasts to reprogram into iPSCs using a non-integrating plasmid.
[0148] Figure 3A shows the reprogramming process using a non-integrating plasmid. The episomal plasmid is electroporated into embryonic fibroblasts of the first generation. The electroporated cells are inoculated into a six-well plate with feeder cells and gradually replaced with the 3i / LAF reprogramming culture system. When the clones grow large enough, they are picked for expansion culture.
[0149] Figure 3B shows the episomal vector reprogramming process (scale bar: 100 μm).
[0150] Figure 3C shows the clone morphology and AP staining results of epi-iPSCs (scale bar: 100 μm).
[0151] The 3D image shows the detection of vector fragment insertion in the epi-iPSCs genome.
[0152] Figure 3E shows the expression of pluripotency genes in epi-iPSCs detected by qPCR.
[0153] Figure 3F shows the expression of pluripotency genes in epi-iPSCs detected by immunofluorescence (scale bar: 50 μm).
[0154] Figure 4 To detect the cell growth characteristics and pluripotency characteristics of 3i / LAF-iPSCs (pMX-iPSCs and epi-iPSCs).
[0155] Figure 4A shows the cell proliferation curve.
[0156] Figure 4B shows the calculation of cell doubling time.
[0157] Figure 4C shows the statistics of single cell adhesion.
[0158] Figure 4D shows the clone morphology and AP staining of high-passage epi-iPSCs (scale bar: 100 μm).
[0159] Figure 4E shows the karyotype identification of high-passage epi-iPSCs.
[0160] Figure 4F-G shows the comet assay to detect the genomic damage of high and low passage 3i / LAF-iPSCs (scale bar: 100μm).
[0161] Figure 4H-I shows the damage and repair status of 3i / LAF-iPSCs at high and low passages (scale bar: 50μm).
[0162] Figure 4J shows the expression detection of pluripotency gene promoter in 3i / LAF-iPSCs.
[0163] Figure 4K shows hematoxylin and eosin staining to detect that the teratoma derived from epi-iPSCs contains the tissue morphology of three germ layers (scale bar: 100μm).
[0164] 4L immunofluorescence staining verified that epi-iPSCs-derived teratomas contained cells from three germ layers (scale bar: 100 μm).
[0165] Detection of the three germ layer differentiation ability of 4M epi-iPSCs (scale bar: 100μm).
[0166] 4N flow cytometry analysis was used to detect the transgenic efficiency of epi-iPSCs.
[0167] 4O epi-iPSCs#5-GFP cell line morphology and GFP fluorescence images (scale bar: 100 μm).
[0168] Figure 5 To induce epi-iPSCs to differentiate into muscle cells.
[0169] 5A is a diagram of the cell status during epi-iPSCs myogenic induction (scale bar: 100 μm).
[0170] 5B shows AP staining during myogenic induction of epi-iPSCs (scale bar: 100 μm).
[0171] 5C is an immunofluorescence staining experiment showing that Stage III differentiated cells express MYOD (scale bar: 100 μm).
[0172] 5D shows the expression of MYOD in Stage V differentiated cells (scale bar: 100 μm).
[0173] 5E shows the expression of F-actin in Stage V differentiated cells (scale bar: 50 μm).
[0174] Figure 6 Transcriptome characterization of 3i / LAF-iPSCs
[0175] Figure 6A shows the correlation analysis between 3i / LAF-iPSCs and pgEpiSCs.
[0176] Figure 6B shows PCA detection of 3i / LAF-iPSCs, pgEpiSCs and PEFs.
[0177] Figure 6C is a ternary plot analysis of 3i / LAF-iPSCs, pgEpiSCs, and PEFs.
[0178] Figure 6D shows the detection of pluripotency gene expression in 3i / LAF-iPSCs.
[0179] Figure 6E shows the enrichment analysis of differentially upregulated genes in 3i / LAF-iPSCs, pgEpiSCs vs PEFs.
[0180] Figure 6F shows that 3i / LAF-iPSCs are closer to the epiblast stem cells of the E10 stage embryo.
[0181] Figure 6G shows that 3i / LAF-iPSCs upregulated EPI representative genes and downregulated Hypo and TE representative genes compared with previously reported PSCs.
[0182] Figure 6H is a heat map of differentially upregulated genes in 3i / LAF-iPSCs compared with pgEpiSCs.
[0183] Figure 6I is a heat map of differentially downregulated genes in 3i / LAF-iPSCs compared with pgEpiSCs.
[0184] Figure 7 To establish a transgene-free iPSCs line from ear fibroblasts of 10-year-old native rare pigs.
[0185] Figure 7A shows the condition of a 10-year-old Wujinhuohair sow.
[0186] Figure 7B shows the status of fibroblasts from a 10-year-old Wujinhuomao sow (scale: 200μm).
[0187] Figure 7C shows the reprogramming process of Wujin pig-iPSCs (scale bar: 100μm).
[0188] Figure 7D shows the process of establishing and expanding the Wujin pig-iPSCs line (scale bar: 100μm).
[0189] Figure 7E shows the AP staining results of Wujin pig-iPSCs (scale bar: 100μm).
[0190] Figure 7F shows the detection of Wujin pig-iPSCs genome integration.
[0191] Figure 7G shows the expression of pluripotency genes in Wujin-epi-iPSCs detected by immunofluorescence staining (scale bar: 50 μm).
[0192] Figure 7H shows the expression of core pluripotency genes in Wujin pig-epi-iPSCs detected by qPCR.
[0193] Figure 7I shows the karyotype detection of Wujin pig-epi-iPSCs.
[0194] Figure 7J shows the development of cloned embryos generated from Wujin pig-epi-iPSCs (scale bar: 100 μm).
[0195] Figure 7K shows the statistics of Wujin pig-epi-iPSCs cloned embryo development efficiency.
[0196] Figure 8 To verify the role of FGF2 and LIF in the establishment of exogenous gene-independent iPSCs lines based on the 3i / LAF system.
[0197] 8A is the correlation analysis of the overall transcriptome levels of exogenous gene-dependent and exogenous gene-independent iPSCs.
[0198] 8B is the analysis of pluripotency gene expression in exogenous gene-dependent and exogenous gene-independent iPSCs.
[0199] 8C uses k-means to analyze the gene expression trends of exogenous gene-dependent and exogenous gene-independent iPSCs.
[0200] 8D is the GO-BP analysis of the gene set with high expression independent of the exogenous gene cell line.
[0201] 8E is the statistical data of the effects of FGF2 and LIF on reprogramming efficiency.
[0202] 8F is the AP staining image of the original induction wells of FGF2 and LIF reprogramming at D18.
[0203] 8G is the induction D12, withdrawal of FGF2, withdrawal of LIF, reprogrammed cell state and fluorescence recording under 3i / LAF system (scale bar: 100 μm).
[0204] 8H is the induction D18, withdrawal of FGF2, withdrawal of LIF, reprogrammed cell status and fluorescence recording under 3i / LAF system (scale bar: 100μm).
[0205] Fig. 9To verify the role of WNT signaling pathway inhibition in exogenous gene-independent iPSCs establishment based on the 3i / LAF system.
[0206] 9A is the GO-BP enrichment analysis of the gene set with low expression of exogenous genes independent of cell lines.
[0207] 9B shows the expression of WNT pathway genes in exogenous gene-dependent and exogenous gene-independent iPSCs.
[0208] 9C shows the induction at D18. After IWR-1 was removed, clone morphology and NANOG-tdTomato fluorescence were observed (scale bar: 100 μm).
[0209] 9D is the induction D20, and the clone morphology and AP staining statistics were produced after IWR-1 was withdrawn (scale bar: 200μm).
[0210] 9E is the expression detection of pluripotency genes and differentiation genes after induction D15 and withdrawal of IWR-1.
[0211] 9F shows the establishment of the line after selecting NANOG-tdTomato positive clones from the IWR-1 system (scale bar: 100 μm).
[0212] 9G shows the cell line established by removing Activin A, LIF, CHIR99021 and Vc (scale bar: 100 μm).
[0213] 9H shows the AP staining of the cell line established by removing Activin A, LIF, CHIR99021, and Vc (scale bar: 100 μm).
[0214] 9I is the detection of exogenous gene expression in cell lines established by removing Activin A, LIF, CHIR99021, WH-4-023, and Vc.
[0215] Fig.10 To compare the establishment of systems under different training systems.
[0216] 10A is the detection of exogenous gene expression in cell lines established under different culture systems.
[0217] 10B is the core pluripotency gene expression detection of cell lines established under different culture systems.
[0218] 10C is GSEA analysis of the WNT signaling pathway activity of GNT-iPSCs under the 3i / LAF system.
[0219] 10D shows the staining of pMX-iPSCs#5β-catenin under the 3i / LAF system (scale bar: 50μm).
[0220] 10E shows the morphology of cell lines established under different culture systems and the fluorescence expression of NANOG-tdTomato (scale bar: 100 μm).
[0221] 10F shows the clone morphology and NANOG fluorescence expression of the cell line established by removing the WH-4-023 system (scale bar: 100 μm).
[0222] 10G Addition of WH-4-023 cells to iPSCs established from the removal of WH-4-023 restored the raised clonal morphology (bar: 100 μm).
[0223] 10H is the detection of gene expression in the three germ layers of iPSCs established under the AFI, AFCI, and 3i / LAF systems.
[0224] 10I is the analysis of EMT-related gene expression in iPSCs after WH-4-023 was removed.
[0225] 10J is the statistics of reprogramming efficiency under different systems. Example
[0226] The invention will now be described with reference to the following examples which are intended to illustrate the invention rather than to limit the invention.
[0227] Those skilled in the art will appreciate that the embodiments describe the present invention by way of example and are not intended to limit the scope of protection claimed in the present application. The experimental methods in the embodiments are conventional methods unless otherwise specified. If specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.
[0228] Experimental Materials
[0229] (1) Mice
[0230] KM mice and BALB / c immunodeficient mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and used for the isolation of mouse embryonic fibroblasts (MEFs) and induced pluripotent stem cells (iPSCs) teratoma formation experiments, respectively.
[0231] (2) Pig
[0232] GNT (GFP random insertion, NANOG-tdTomato knock in, and TYR homozygous knockout) pig ear fibroblasts (GNT-pEFs) were isolated from cloned piglets produced by nuclear transplantation of GNT-pgEpiSCs, which were raised and provided by the Northern Animal Research Base of the Chinese Academy of Sciences. The ovaries used in the iPSCs cloning experiment were collected from the Yunnan pig slaughterhouse. pgEpiSC refers to pig pregastrulation epiblast pluripotent stem cells, see Zhi, M., Zhang, J., Tang, Q. et al. Generation and characterization of stable pig pregastrulation epiblast stem cell lines. Cell Res 32, 383-400 (2022).
[0233] (3) Cell lines
[0234] The porcine fetal fibroblast cell line (obtained from 26-day-old fetuses of Nongda Xiang pigs) and GNT pig adult ear fibroblasts were isolated by our laboratory; the adult ear fibroblasts of the local pig breed Wujinhuomao were kindly donated by Professor Wei Hongjiang of Yunnan Agricultural University; the virus packaging cell line GP2-293 was purchased from ATCC; the fibroblasts used for mouse feeder layer cells were isolated from 13.5-day-old fetuses of KM mice.
[0235] (4) Primers
[0236]
[0237]
[0238] (5) Plasmid
[0239] Retroviral reprogramming system: The retroviral plasmid pOSKM was kindly donated by Ruan Weimin's laboratory at Henan University; the capsid protein plasmid pVSVG was retained by our laboratory.
[0240] The non-integrating reprogramming plasmids Episomal pEV-hOCT4-SOX2, Episomal pEV-hKLF4, Episomal pEV-hC-MYC, and Episomal pEV-hBCL2L1 (Episomal iPSC Reprogramming Kit, 611005) were purchased from Jinhuai Biopharmaceutical Technology (Tianjin) Co., Ltd. Episomal pEV-pLIN28A and Episomal pEV-pNANOG were constructed for this project. The construction method is as follows: Pig NANOG and LIN28A fragments were amplified from the cDNA of low-generation pig pgEpiSCs. Amplification primers with homology arms were generated using SnapGene In Fusion Cloning. PrimeSTAR GXL DNA Polymerase (TaKaRa, R050A) was used for amplification. After the PCR reaction was completed, electrophoresis was performed in 1% agarose gel. After the electrophoresis was completed, the target band was cut under a UV gel irradiator. DNA fragments were recovered using the OMEGA gel recovery kit (D2000-02). The pEV-hKLF4 vector was digested with Kpn I and Not I using the non-integrated vector pEV-hKLF4 vector backbone vector. After the digestion reaction, 1% agarose gel was used for electrophoresis, and the backbone vector was recovered in the same way as above to recover the target fragment. The target fragment and the linearized vector after digestion were assembled using NEBuilder HiFi DNA Assembly Master Mix (E2621L). The assembled product was added to Trans5α for transformation. Positive colonies were identified by PCR, and some of the positive colony culture fluids were taken for Sanger sequencing. The sequencing results were compared with the target fragment DNA, and the culture fluid with the correct fragment was expanded to harvest the pEV-pNANOG and pEV-pLIN28A vectors.
[0241] GFP integration plasmid: pCAGPBase plasmid was donated by Wu Sen Laboratory of China Agricultural University; PB-CMV-EF1A-GFP-NLS plasmid was retained by our laboratory.
[0242] Single-base editing plasmid: pGL3-U6-MSTN gRNA-EGFP was designed and constructed by Gao Jie in our laboratory; pCMV_AncBE4max was donated by Professor Huang Xingxu.
[0243] (6) Small molecule compounds and recombinant proteins:
[0244]
[0245]
[0246] (7) Antibodies:
[0247]
[0248]
[0249] (8) Cell culture reagents
[0250]
[0251] (9) Kit
[0252]
[0253]
[0254] (10) Culture medium
[0255] MEF / PEF Culture Medium
[0256] Basic culture medium
[0257]
[0258] 3i / LAF medium
[0259] AFI medium
[0260] AFCI medium
[0261]
[0262] ALCIW medium
[0263] LCDMV medium
[0264]
[0265] FL6i medium
[0266]
[0267] FL3i Medium
[0268]
[0269] Differentiation medium
[0270]
[0271] Experimental methods
[0272] 1. Retroviral system induced reprogramming
[0273] (1) The low-passage porcine fibroblasts (no more than 5 generations) used for resuscitation and reprogramming were subcultured after the cells were fully grown, and the fibroblast growth coverage was as high as possible to reach about 70% 24 hours after subculture;
[0274] The fibroblasts include pig embryonic fibroblasts (PEFs) and adult pig ear fibroblasts (pEFs).
[0275] (2) Take 200 μL of freshly packaged pig OSKM virus solution and add it to 1.3 mL of PEF medium. Continue to add Polybrene to a final concentration of 8 μg / mL.
[0276] (3) Add 1.5 mL of the above liquid evenly to the fibroblasts and incubate them in a 37°C incubator overnight for 12 h;
[0277] (4) Replace with fresh PEF medium and continue to culture virus-infected fibroblasts;
[0278] (5) Three days after virus infection, virus-infected cells were seeded into six-well plates containing feeder cells at a density of 4 × 104 cells per six-well plate;
[0279] (6) After culturing in PEF medium for 24 h, the medium was replaced with fresh 3i / LAF medium for induction;
[0280] (7) After a colony with a convex shape and clear and bright edges appears in the induction well, use a mouth pipette to pick up the target clone and use Accutase enzyme to properly digest the cell clone;
[0281] (8) Use 3i / LAF medium to neutralize the digested cell clumps, and use a pipette to blow the cells until smaller clumps are formed;
[0282] (9) Transfer the small cell clumps to a 48-well plate covered with a feeder layer for culture;
[0283] (10) After 48 hours, replace the culture medium with fresh one. After the clones grow, digest and subculture them into 24-well plates for culture and expansion.
[0284] (11) After the cells can be stably propagated to a 6-well plate, freeze them for seed storage.
[0285] 2. Non-integrating vector-induced reprogramming
[0286] (1) Resuscitating fibroblasts, culturing for one generation in vitro, and digesting the fibroblasts with 0.25% Trypsin-EDTA when the cells are fully grown. The digestion is terminated when the cells become round.
[0287] The fibroblasts include porcine embryonic fibroblasts or adult porcine ear fibroblasts.
[0288] (2) Mix the electroporation solutions S1 and S2 evenly, and add 2 μg pEV-hOCT4-hSOX2, 1 μg pEV-hKLF4, 1 μg pEV-hC-MYC, and 0.5 μg pEV-hBCL2L1. During the induction of adult fibroblasts, 1 μg pEV-pLIN28A and 1 μg pEV-pNANOG can be added to improve the reprogramming efficiency.
[0289] (3) Take 5×10 5 The fibroblasts were centrifuged and the supernatant was removed, and washed once with DPBS;
[0290] (4) Resuspend the cell pellet with electroporation solution and plasmid mixture, and transfer the suspension into the electroporation cup;
[0291] (5) Electroporation was performed using a BTX ECM2001 instrument with the parameters set to 340 V, 1 ms, and 3 pulses;
[0292] (6) After electroporation, immediately add 1×10 5 The cells were transferred into six-well plates containing feeder cells;
[0293] (7) After 24 h, the PEF medium was replaced with a 1:1 system of PEF and 3i / LAF medium and the culture was continued;
[0294] (8) After 24 h, the 1:1 system of PEF and 3i / LAF medium was replaced with complete 3i / LAF medium;
[0295] (9) After the clones with clear and bright edges and convex morphology are produced, use a pipette to pick up the cell clones, digest them and blow them into small cell clumps;
[0296] (10) Continue culturing until iPSCs can be stably cultured in a 6-well plate.
[0297] 3. Cell growth curve drawing and doubling time calculation
[0298] 2×10 5 Inoculate 12 cells into the wells of a 12-well plate with feeder cells, and record the number of feeder cells at this time. Then use LunaTM automatic counter to record the number of cells every 12 hours, and continue to record until 72 hours after subculturing. Make 3 replicate wells at each time point. Plot the graph based on the recorded cell numbers.
[0299] The doubling time was calculated at 24h and 48h after subculture.
[0300] Doubling time (DT) = 24 × [lg2 / (lgN48h-lgN24h)]
[0301] 4. Analysis of monoclonal formation efficiency
[0302] Digest the cells in the proliferation phase and repeatedly blow them to make them single cells, and further remove the feeder layer cells by differential adhesion method. Under a microscope, use a mouth pipette to pick up cells with good morphology and inoculate them into a 24-well plate with feeder layer cells. Put 200 single cells in each well and replace it with fresh culture medium after 48 hours. Thereafter, change the medium every 24 hours. After 1 week, AP stain the culture wells and count the number of AP positive clones. According to the number of positive clones, calculate the single cell clone formation rate.
[0303] 5. Preparation and Differentiation of Embryoid Bodies
[0304] When iPSCs are in the vigorous proliferation period, use 0.02% EDTA dissociation solution to digest cell clones to remove feeder cells, and use Accutase to further digest the cells into single cells, and collect cell pellets. Resuspend the cell pellets with differentiation medium (3i / LAF basal medium + 2ng / mL FGF2 + 5% FBS), inoculate the cells in non-adherent 35mm dishes, and culture them in a 37℃ incubator at 20rpm. Replace half of the medium with fresh medium every day.
[0305] After 3 days of suspension culture, regular spheres with smooth edges can be seen in the culture dish. The spheres in good condition are taken out and placed in a 4-well plate for culture. After 1 week of adherent culture, they are fixed with 4% PFA and immunofluorescence staining of the three germ layers is performed. Observe whether cells of the three germ layers can be differentiated
[0306] 6. Teratoma injection
[0307] When iPSCs were in the vigorous proliferation period, cells were digested with Accutase and 1×10 7Cells were collected by centrifugation. Matrigel and 3i / LAF medium were prepared in equal proportions, and Y-27632 was supplemented to a final concentration of 10 μM. 200 μL of the above liquid was taken to resuspend the cell pellet, and the suspension was kept at low temperature and injected into the back of the nude mouse's neck. The injected nude mice were carefully cultured in the SPF mouse room for 4-8 weeks.
[0308] 7. Directed differentiation of three germ layers
[0309] The process of directed differentiation of the three germ layers is as follows:
[0310] (1) Ectodermal differentiation: 48 hours after iPSCs were subcultured, the 3i / LAF system was replaced with BM+IWR-1 (2.5μM)+SB431542 (5μM)+FGF2 (10ng / mL) culture medium; after 48 hours of culture, the culture medium was replaced with BM+RA (4μM)+FGF2 (10ng / mL)+Noggin (20ng / mL). After 48 hours of culture, the cells were fixed with 4% PFA and SOX1 expression was detected by immunofluorescence staining;
[0311] (2) Mesoderm differentiation: 48 hours after iPSCs were subcultured, the 3i / LAF system was replaced with BM+BMP4 (10 ng / mL)+ActivinA (50 ng / mL)+FGF2 (20 ng / mL) culture medium; after 48 hours of culture, the culture medium was replaced with BM+IWR-1 (3 μM)+CHIR99021 (5 μM)+FGF2 (20 ng / mL). After 48 hours of culture, the cells were fixed with 4% PFA and the expression of T was detected by immunofluorescence staining;
[0312] (3) Endoderm differentiation: 48 hours after iPSCs were passaged, the 3i / LAF system was replaced with BM+BMP4 (10 ng / mL)+SB431542 (5 μM)+FGF2 (10 ng / mL), and the cells were passaged after they showed fibroblastic state. After passage, the cells were immunostained when they were confluent, and the expression of GATA6 was detected by immunofluorescence staining.
[0313] 8. Transcriptome sequencing and analysis
[0314] 48-60h after iPSCs were passaged, the cell clones were digested with 0.02% EDTA dissociation solution, the suspension was collected, centrifuged at 1,000rpm for 8min, the supernatant was removed, 1mL Trizol was added, and the cells were immediately stored in a -80℃ refrigerator. Transcriptome library construction and sequencing were completed by Beijing Tangtang Tianxia Biotechnology Co., Ltd. Other transcriptome data cited in this study are as follows.
[0315]
[0316]
[0317] 9. Construction of cloned embryos and evaluation of their developmental capacity
[0318] iPSCs were differentiated into fibroblasts according to the endoderm differentiation strategy in the directed differentiation method, and the differentiated fibroblasts were used as donor cells for nuclear transplantation. Oocytes with three or four layers of cumulus cells were selected and cultured to the metaphase stage of meiosis II, and then the nucleus was removed using a micromanipulator. Donor cells in good condition were selected and injected into the yolk space of the enucleated oocytes. The electrocell Fusion Generator (LF201, Nepa Gene, Chiba, Japan) was used at an amplitude of 200V / mm for 20μs to mediate the fusion of reconstructed embryos. The reconstructed embryos were activated by acting at an amplitude of 150V / mm for 100μs. The embryos were first cultured in PZM-3 medium containing 5μg / mL cytochalasin B at a constant temperature of 39℃, containing 5% CO2, 5% O2, and 90% N2 for 2h, and then replaced with PZM-3 medium and cultured to the blastocyst stage. The number of cleavage embryos and blastocysts was counted during embryonic development.
[0319] 10. Data Processing
[0320] The error in the data chart is represented by SD. The significance analysis between the two groups of data was performed using the t-test. P < 0.05 was considered significant, where P < 0.05 was represented by *, P < 0.01 was represented by **, and P < 0.001 was represented by ***.
[0321] Example 1: Establishment of exogenous genes from GNT-pEFs independent of iPSCs
[0322] In order to promote the accurate and efficient acquisition of fully reprogrammed iPSCs under the 3i / LAF system, this study used the NANOG-tdTomato reporter system fibroblast cell line as the induction starting cell line. This cell line was isolated from the ear margin tissue of cloned piglets with random GFP insertion, NANOG-tdTomato Knock in, and TYR homozygous knockout (GNT) generated in our laboratory earlier, and the tissue can show green fluorescence. The isolated GNT fibroblast cell line (GNT-pEFs) has good morphology, expresses GFP, and does not express NANOG-tdTomato fluorescence. The obtained fibroblasts were identified by genomic PCR, and the insertion of the tdTomato reporter system at the NANOG stop codon of the obtained GNT-pEFs was verified. The above results show that a fibroblast cell line carrying the NANOG-tdTomato reporter system was obtained.
[0323] After obtaining GNT-pEFs, this study used the fibroblasts as the starting cells and used the retroviral induction system to induce iPSCs. The reprogramming process of iPSCs is as follows ( Figure 1 A), GNT-pEFs were subcultured once after recovery, and the virus infection was performed 24 hours after subculture. The time of virus infection was recorded as Day 0. After 12 hours of virus infection, the medium was replaced with fresh PEF medium. After 72 hours of virus infection, the cells were digested into single cells and plated at 4×10 4 The cells were inoculated into the wells with feeder cells. After 24 hours of plating, the medium was replaced with 3i / LAF induction medium. Seven days after virus infection (Day 7), fibroblasts were obviously deformed, and NANOG expression was not activated at this time. Sixteen days after virus infection (Day 16), clones with smooth edges and raised morphology were generated, and tdTomato fluorescence could be observed ( Figure 1 B). AP staining is the basic evaluation index for pluripotency identification. AP staining was performed on the original induced wells, and the number of AP-positive clones was counted. The results showed that there were 85 AP-positive clones in each well on average, and the induction efficiency was about 0.21%. Combined with the analysis of NANOG activation in the induced wells, the results showed that approximately 95.91% of AP-positive clones were able to activate NANOG expression, and the efficiency of endogenous pluripotency gene activation was close to the efficiency of endogenous gene activation during mouse iPSCs induction (Han et al., 2010). Clones expressing tdTomato fluorescence, smooth edges, and moderate size were selected for expansion and culture, and iPSCs lines (GNT-iPSCs) that can be stably passaged can be obtained within 5 generations. The established iPSCs line clones have uniform growth status, are dome-shaped, and have bright edges. Almost all GNT-iPSCs clones can show tdTomato fluorescence ( Figure 1 C, D). The above results show that the 3i / LAF system can efficiently establish iPSCs lines with uniform pluripotency.
[0324] In iPSCs generated by retroviral reprogramming, retroviral silencing is one of the hallmarks of high-quality iPSCs. The results of qPCR showed that compared with GNT-pEFs 3 days after viral infection, the exogenous genes of the five randomly selected GNT-iPSCs lines (GNT-iPSCs#1,#3,#9,#10,#11) were all in a silent state ( Figure 1 E).
[0325] In order to further verify the pluripotency of GNT-iPSCs, GNT-iPSCs were subjected to pluripotency marker gene immunofluorescence staining. The results of immunofluorescence staining showed that GNT-iPSCs expressed the core pluripotency genes OCT4 and SOX2, and also expressed pluripotent stem cell-specific surface marker genes SSEA1, SSEA4, TRA-1-60 and TRA-1-81. The above results show that GNT-iPSCs have pluripotency characteristics ( Figure 1 F).
[0326] Example 2: Establishment of exogenous genes from wild-type fibroblasts independent of iPSCs
[0327] In this study, wild-type PEFs were used as starting cells for the induction of iPSCs. Figure 1 A. On the 6th day after virus infection (Day 6), fibroblasts underwent obvious mesenchymal-to-epithelial transformation and presented an epithelial-like morphology; on the 12th day after virus infection (Day 12), clones with clear edges and convex morphology were generated ( Figure 2 A). The iPSCs line derived from a single clone (pMX-iPSCs) showed an ESC-like morphology and was positive for AP staining ( Figure 2 B). The induction efficiency of AP positive clones reached 0.4% ( Figure 2 C), which is higher than the induction efficiency of adult fibroblasts. The four randomly selected pMX-iPSCs (pMX-iPSCs#1, #2, #6, #10) were able to silence exogenous genes ( Figure 2 D). The retroviral vector was integrated into the genome of all four iPSCs ( Figure 2 E). Next, the expression of core pluripotency genes in pMX-iPSCs was analyzed. Immunofluorescence staining results showed that pMX-iPSCs expressed core pluripotency genes OCT4, SOX2, and NANOG ( Figure 2 G). qPCR further demonstrated the expression of endogenous pluripotency genes OCT4, SOX2, KLF4, C-MYC, and other key pluripotency genes NANOG, REX1, LIN28A, SALL4, and OTX2, and the expression level of pluripotency genes in pMX-iPSCs was close to that in pgEpiSCs ( Figure 2 F). The above results further verified that the 3i / LAF system has the ability to generate fully reprogrammed iPSCs.
[0328] Example 3: Establishment of iPSCs lines without exogenous gene integration
[0329] Episomal vector-induced method has attracted much attention due to its wider application range, simple operation and clinical application value. In this study, Episomal vector was used to mediate exogenous gene expression and further develop iPSCs without exogenous gene integration.
[0330] The Episomal vector backbone (pEV) used in the experiment contains the spleen focus forming virus promoter (SFFV), the cis-acting RNA element WPRE that improves the expression and translation of the target gene, and the OriP and EBNA1 elements that keep the exogenous gene in the form of free bodies in eukaryotic cells and promote the nuclear entry and transcription of the target gene. These elements can promote the efficient expression of exogenous target genes in eukaryotic cells. The reprogramming factors include 5 protein-coding genes including human OCT4, SOX2, KLF4, C-MYC and BCL2L1. Among them, OCT4 and SOX2 are used in series, and the anti-apoptotic factor BCL2L1 is added on the basis of the classic 4 factors (Wen et al., 2016).
[0331] Reprogramming using pEV series vectors can be divided into the following steps: When the cell coverage reaches about 90%, digestion and counting are performed, and 5×10 5 After electroporation, cells were plated at 1×10 5 The cells were inoculated at a density of 1.50 μg / mL in the wells containing feeder cells prepared 12 h in advance. After culturing with fibroblast medium for 24 h, the medium was replaced with 1 / 2 3i / LAF medium to ensure that the cells could gradually adapt to the 3i / LAF reprogramming system. The next day, the medium was replaced with complete reprogramming medium ( Figure 3 A). Three days after electroporation (Day 3), epithelial-like cells began to appear and gradually aggregated into clusters until the 18th day of induction (Day 18), when ESC-like clones with clear and smooth edges and convex morphology were formed ( Figure 3 B) From 1×10 5 From the starting cells, a total of 11 iPSCs clones (epi-iPSCs) were obtained, with a reprogramming efficiency of 0.011%. This reprogramming efficiency is consistent with the reprogramming efficiency of iPSCs mediated by the human Episomal system (Schlaeger et al., 2015). From the 11 starting clones, except for 3 clones that differentiated and failed to establish a lineage during the expansion culture process, the other 8 clones were able to stably expand and culture and form cell lines. The established epi-iPSCs clones are three-dimensional, have clear edges, are AP-positive, and have the basic characteristics of pluripotency ( Figure 3 C). The above results show that iPSCs can be obtained by delivering exogenous genes using Episomal vectors in the 3i / LAF system.
[0332] As cell division proceeds, Episomal vector fragments will gradually be lost. In order to further verify whether the obtained iPSCs are cell lines without transgene integration, this study detected the residual status of Episomal vector fragments in the genome of iPSCs cultured for the 8th generation. First, the EBNA1 and WPRE fragments on the vector backbone were detected, and the test results showed that 87.5% (7 / 8) of the cell lines had no EBNA1 and WPRE residues. Since non-integrated vectors may be fragmented and still remain in the cells in a fragmented form, the genomic residue status of a single reprogramming factor was further detected. The test results showed that all the obtained cell lines had no exogenous SOX2, KLF4, C-MYC and BCL2L1 fragments remaining, and 50% of the cell lines had no OCT4 fragments remaining ( Figure 3 D). In general, 50% of the iPSCs obtained were at a lower generation, that is, without exogenous gene residues. In order to verify whether the obtained iPSCs without exogenous gene integration have the basic characteristics of pluripotent stem cells, this study detected the expression of pluripotency genes in epi-iPSCs without exogenous gene integration by qPCR and immunofluorescence staining experiments. The qPCR results showed that the obtained iPSCs were able to express the core pluripotency genes OCT4, SOX2, and NANOG, as well as other pluripotency marker genes KLF4, C-MYC, REX1, LIN28A, SALL4, and OTX2, and the expression level of pluripotency genes was close to that of pgEpiSCs ( Figure 3 E). Immunofluorescence staining results showed that epi-iPSCs expressed OCT4, SOX2 and NANOG core pluripotency genes ( Figure 3 F). The above results indicate that the epi-iPSCs obtained without exogenous gene integration have basic pluripotency gene characteristics.
[0333] Example 4: Identification of 3i / LAF-iPSCs cell characteristics
[0334] The above examples obtained pMX-iPSCs with exogenous gene silencing under the 3i / LAF system and epi-iPSCs without exogenous gene integration in the genome (collectively referred to as 3i / LAF-iPSCs). This example will conduct detailed identification of the obtained iPSCs in terms of cell growth characteristics, stability, multidirectional differentiation potential, etc., in order to provide effective reference value for the application potential of iPSCs.
[0335] 4.1 Growth characteristics
[0336] In order to clarify the growth characteristics of 3i / LAF-iPSCs, its growth and proliferation were first described. 3i / LAF-iPSCs can be enzymatically hydrolyzed into single cells for subculture. Subculture is performed every 2-3 days at a ratio of 1:3. The growth curve plotting results show that 3i / LAF-iPSCs enter a rapid proliferation state (12 hours after subculture). Figure 4 A), the cell doubling time is about 18h ( Figure 4 B), the efficiency of single cell clone formation is about 30% ( Figure 4 C). The cell growth characteristics of 3i / LAF-iPSCs were close to those of pgEpiSCs, and there was no significant difference in the iPSCs induced by different systems.
[0337] 4.2 Self-renewal capability
[0338] In order to detect the self-renewal ability of iPSCs cultured in vitro for a long time, two iPSCs cell lines were randomly selected for long-term subculture in vitro. After more than 200 days of continuous culture, this study cultured 3i / LAF-iPSCs to more than 100 generations, and the cells were still able to maintain clear edges and raised morphology, and AP staining was positive. The expression of core pluripotency genes was detected by qPCR, and the results showed that the core pluripotency genes of high-generation iPSCs were all expressed normally. Therefore, 3i / LAF-iPSCs can still maintain self-renewal ability after long-term culture.
[0339] 4.3 Genome stability
[0340] In order to evaluate the genomic stability of 3i / LAF-iPSCs after long-term culture, this study tested the genomic stability of high-generation 3i / LAF-iPSCs from different angles, including karyotype analysis, comet assay, and γH2A.X staining. The results of karyotype analysis showed that epi-iPSCs were able to maintain the normal 38 chromosomes at high generations, and long-term culture did not cause the number of chromosomes in 3i / LAF-iPSCs to change ( Figure 4 E).
[0341] The comet assay is a relatively sensitive and effective method for evaluating DNA damage. In cells with DNA damage, broken DNA will migrate out of the nucleus under the action of the electric field, forming a tail on one side of the nucleus. The length of the tail can reflect the degree of DNA damage. H2O2 treatment can induce DNA damage in cells, so this study used low-generation pMX-iPSCs treated with H2O2 as the positive control of the experiment. The experimental results showed that the H2O2-treated wells showed obvious tailing, while high- and low-generation iPSCs did not show obvious tailing ( Figure 4F). Comet analysis software was used to perform statistical analysis on the tail distances of 50 single cells, and no significant difference was found between high and low generations ( Figure 4 G). The above results indicate that no obvious DNA damage occurred in 3i / LAF-iPSCs after long-term culture.
[0342] γH2A.X immunofluorescence can clearly reflect the status of DNA damage and repair. The results of γH2A.X immunofluorescence staining showed that compared with low-generation iPSCs, the number of γH2A.X-positive cells in high-generation iPSCs did not increase ( Figure 4 H). 20 fields of view were taken for statistical analysis, and the statistical results showed that there was no significant difference in the proportion of γH2A.X positive cells between high-passage iPSCs and low-passage iPSCs ( Figure 4 I). In conclusion, 3i / LAF-iPSCs can maintain genomic stability under long-term culture.
[0343] 4.4 Methylation status of pluripotency gene promoters
[0344] The methylation level of the promoter region is negatively correlated with gene expression. The methylation level of the promoter can reflect the activity of gene expression. In order to further describe the expression activity of the core pluripotency genes OCT4 and NANOG in 3i / LAF-iPSCs, this study used bisulfite modified sequencing to detect the methylation level of their promoters. The detection results showed that the methylation level of the OCT4 promoter in pMX-iPSCs#6 decreased from 35.45% to 0.00%, and the methylation level of the NANOG promoter decreased from 23.33% to 0.00%; the methylation level of the OCT4 promoter in pMX-iPSCs#10 decreased from 35.45% to 0.90%, and the methylation level of the NANOG promoter decreased from 23.33% to 0.00%; the methylation level of the OCT4 promoter in epi-iPSCs#5 decreased from 35.45% to 1.81%, and the methylation level of the NANOG promoter decreased from 23.33% to 0.00%; the methylation level of the OCT4 promoter in epi-iPSCs#8 decreased from 35.45% to 2.72%, and the methylation level of the NANOG promoter decreased from 23.33% to 1.67% ( Figure 4 J). The above results showed that the promoters of the core pluripotency genes OCT4 and NANOG in 3i / LAF-iPSCs were in a low methylation state.
[0345] 4.5 Random Differentiation Potential
[0346] In order to detect the multidirectional differentiation ability of 3i / LAF-iPSCs, this study conducted an in vivo teratoma formation experiment on 3i / LAF-iPSCs to detect its random differentiation potential. 7pMX-iPSCs and epi-iPSCs were injected subcutaneously into nude mice separately, and teratomas were formed in 6-8 weeks. The DNA of teratoma tissue was extracted for genomic PCR detection, and pig reference gene fragments were detected in the teratoma genome. The results showed that the teratoma formed was differentiated from the injected pig iPSCs. Among them, the teratoma formed by pMX-iPSCs still had detectable reverse transcription vector fragments inserted in the genome. H&E staining of teratoma tissue revealed obvious ectoderm (neural tube), mesoderm (muscle cells), and endoderm (intestinal epithelial cells) structures ( Figure 4 K). The teratoma immunofluorescence staining experiment further proved that the differentiated teratoma contained cells from three germ layers, Tubulinβ-Ⅲ positive cells represented the ectoderm, α-SMA positive cells represented the mesoderm, and GATA6 positive cells represented the endoderm ( Figure 4 L). The above results indicate that 3i / LAF-iPSCs have the ability to randomly differentiate into three germ layers in vivo and in vitro.
[0347] 4.6 Directed Differentiation Ability
[0348] iPSCs have multidirectional differentiation potential and can form specific types of cells by inducing differentiation to specific germ layers in vitro. The realization of directed differentiation depends on the induction and regulation of germ layer-specific signaling pathways. Retinoic acid (RA) mediates the differentiation of embryonic stem cells into neurons; BMP signals inhibit the occurrence of neural fate and promote the differentiation of mesendoderm. Noggin protein is an antagonist of BMP4, so it plays a role in promoting ectoderm differentiation. The combination of WNT activators and inhibitors can promote the directed differentiation of mesoderm. SB431542 can inhibit mesoderm differentiation. Since epi-iPSCs do not have the integration of exogenous vector fragments, they have greater value in practical applications. This study tested the ability of epi-iPSCs to differentiate into different germ layers. The experimental results showed that epi-iPSCs can also differentiate into specific germ layers under the induction of the above-mentioned small molecule combination culture system. Immunofluorescence staining experiments proved that epi-iPSCs can differentiate into three germ layers. The above results show that epi-iPSCs in the 3i / LAF system can be induced to differentiate into cells of specific germ layers ( Figure 4 M).
[0349] 4.7 Transgenic Capability
[0350] The use of porcine iPSCs for gene modification to generate complex disease models has great application value in the field of medical research. In order to evaluate the gene modification ability of epi-iPSCs, this study transferred randomly integrated GFP vectors into epi-iPSCs and evaluated the transfection efficiency based on the proportion of GFP-positive cells. 72 hours after transfection, iPSCs expressed GFP fluorescence. Flow cytometry analysis results showed that the proportion of epi-iPSCs expressing GFP-positive signals was 22.2%, which is consistent with the reported transfection efficiency of pgEpiSCs (Zhi et al., 2021)( Figure 4 N). After the transfected cells were passed for 3 generations, GFP-positive cells were selected for amplification and culture, and a cell line carrying the GFP transgene was obtained ( Figure 4 O). The above results indicate that 3i / LAF-iPSCs have efficient transgenic ability.
[0351] Example 5: Preparation of cultured meat
[0352] At present, traditional animal husbandry is facing many severe challenges, which requires a new meat production model, and animal cell cultured meat has emerged. Seed cells are the key factor in the development of cell cultured meat. Compared with muscle stem cells and mesenchymal stem cells, pluripotent stem cells are more suitable for large-scale culture expansion and directional differentiation. In the previous study, epi-iPSCs without exogenous gene integration were obtained, which are expected to be used as seed cells for the development of cell cultured meat. Therefore, this study tested the ability of epi-iPSCs to differentiate into muscle cells. First, epi-iPSCs in the proliferation stage were digested into clumps, and Stage I medium (DMEM / F12 supplemented with B27 1%, CHIR99021 3uM, SB431542 2μM, NEAA 1%, β-mercaptoethanol 0.1%, Penicillin-Streptomycin (100×) 1%, KOSR 15%, ascorbic acid 200uM) was used to promote cell adhesion and differentiation. After 2-3 days of culture, differentiated cells can be seen gradually extending from the periphery of the clone. When the cell confluence reaches 100%, the cells are passaged in a single cell manner, and after the cells adhere to the wall, they are replaced with Stage II medium (DMEM / F12 supplemented with LDN193189 0.5μM, FGF2 20ng / mL, CHIR99021 3μM, NEAA 1%, β-mercaptoethanol 0.1%, Penicillin-Streptomycin (100×) 1%, KOSR 15%, ascorbic acid 200uM).The cells were passaged in this manner and gradually replaced with Stage III medium (DMEM / F12 supplemented with HGF 10 ng / mL, IGF-1 10 ng / mL, FGF2 20 ng / mL, LDN193189 0.5 μM, NEAA 1%, β-mercaptoethanol 0.1%, Penicillin-Streptomycin (100×) 1%, KOSR 15%, ascorbic acid 200 uM), Stage IV medium (DMEM / F12 supplemented with IGF-1 10 ng / mL, NEAA 1%, β-mercaptoethanol 0.1%, Penicillin-Streptomycin (100×) 1%, KOSR 15%, ascorbic acid 200 uM), and Stage V medium (DMEM / F12 supplemented with IGF-1 10 ng / mL, HGF 10 ng / mL, NEAA 1%, β-mercaptoethanol0.1%, Penicillin-Streptomycin(100×)1%, KOSR 15%, ascorbic acid 200uM in DMEM / F12). When differentiated to Stage IV, the cells were negative for AP staining, indicating that the iPSCs cells were completely differentiated (. Figure 5 B). Myogenic differentiation (MYOD) is a signature transcription factor that regulates the fate transition of skeletal muscle cells. When cells differentiate to Stage III, immunofluorescence staining shows that MYOD expression is activated, indicating that muscle precursor cells are formed ( Figure 5 C). After switching to Stage V medium, the cells showed a distinct fibrous morphology with orientation ( Figure 5 A). The expression of actin MYOSIN is a sign of muscle fiber differentiation. MYOSIN is highly expressed during the differentiation to Stage V ( Figure 5 D). F-actin is also widely distributed in differentiated cells ( Figure 5 E). The results showed that epi-iPSCs have the ability to differentiate into muscle cells and thus produce cultured meat.
[0353] Example 6: Analysis of pluripotency characteristics of 3i / LAF-iPSCs at the transcriptome level
[0354] This study further conducted a systematic transcriptome analysis of 3i / LAF-iPSCs to further characterize the characteristics of 3i / LAF-iPSCs. The transcriptome analysis mainly included the following three aspects: (1) similarity analysis between 3i / LAF-iPSCs and pgEpiSCs; (2) comparative analysis between 3i / LAF-iPSCs and reported porcine PSCs; (3) searching for 3i / LAF-iPSCs-specific gene expression networks through weighted gene co-expression network analysis (WGCNA).
[0355] 6.1 Similarities between 3i / LAF-iPSCs and pgEpiSCs
[0356] Transcriptome sequencing was performed on 3i / LAF-iPSCs (GNT-iPSCs, pMX-iPSCs and epi-iPSCs) established in the above examples. Pearson correlation coefficient analysis showed that compared with PEFs, 3i / LAF-iPSCs and pgEpiSCs showed greater similarity at the overall transcriptome level ( Figure 6 A). The results of principal component analysis (PCA) showed that 3i / LAF-iPSCs and pgEpiSCs were consistent in PC1 ( Figure 6 B). The high-density region including pluripotency genes in the ternary plot is distributed between 3i / LAF-iPSCs and pgEpiSCs. The pluripotency gene expression heat map further showed that 3i / LAF-iPSCs and pgEpiSCs had consistent pluripotency gene expression levels, among which the expression levels of OCT4, LIN28A, and DNMT3B were most significantly different between 3i / LAF-iPSCs and PEFs. The above results show that 3i / LAF-iPSCs and pgEpiSCs have similarities.
[0357] This study further analyzed the differential signaling pathways between 3i / LAF-iPSCs and PEFs. From the Venn diagram of differentially expressed genes between 3i / LAF-iPSCs / pgEpiSCs and PEFs, it can be found that PSCs upregulated 1066 genes. The functional enrichment analysis results of these differentially expressed genes showed that 3i / LAF-iPSCs upregulated signaling pathways such as maintenance of stem cell characteristics (such as maintenance of stem cell populations, determination of stem cell fate, negative regulation of stem cell differentiation and stem cell division), regulation of pluripotency (such as FGF and LIF signal response, SMAD protein signal transduction, negative regulation of WNT signaling pathway), and early embryonic development (such as inner cell mass cell differentiation, blastocyst formation). Figure 6E). The above results indicate that 3i / LAF-iPSCs significantly upregulated stem cell pluripotency maintenance and development-related pathways.
[0358] During the embryonic development stage, the cells in the embryo gradually develop and specialize, experiencing the changes from the totipotency of the entire blastomere before specialization, to the naive pluripotency, formative pluripotency, primed pluripotency and loss of pluripotency of the epiblast after specialization. The correspondence between the stem cells isolated in vitro and the pluripotency stage in the embryonic development process can further characterize their pluripotency state. The PCA analysis results showed that 3i / LAF-iPSCs and pgEpiSCs could be clustered together, but did not overlap with the embryonic development stage, but clustered separately. This may be because cells cultured in vitro are difficult to completely approach cells in vivo in terms of metabolism, signal communication, etc. Overall, 3i / LAF-iPSCs are close to the epiblast cells of E10-E14 embryos. The consistency score analysis of 3i / LAF-iPSCs and the epiblast cells of E10-E14 embryos further showed that 3i / LAF-iPSCs are closer to the epiblast cells of E10 embryos ( Figure 6 F). The above results indicate that 3i / LAF-iPSCs are closer to the epiblast cells of E10 embryos.
[0359] The results of differential gene analysis between 3i / LAF-iPSCs and pgEpiSCs showed that 11 genes were up-regulated in all 3i / LAF-iPSCs, and 20 genes were down-regulated in all 3i / LAF-iPSCs ( Figure 6 These differentially expressed genes were mainly involved in response to stimulation (NR4A1, NR4A2, NR4A3, FOSB, and CCN2), metabolism (FABP3, FN3KRP, DNPH1, CCN1, THBS1, and RPL26), and signal transduction (ANXA1, RUSC1, SNX1, EGR4, and DUSP2), but not in pluripotency, stemness, and development-related pathways.
[0360] 6.2 Comparative analysis of 3i / LAF-iPSCs and reported PSCs cell lines
[0361] This study further compared the transcriptome of 3i / LAF-iPSCs with that of PSCs under other reported systems, including cells under FGF2, LIF, 2i / LIF (MEKi, GSK3βi), FLB2i (FGF2, LIF, BMP4, GSK3αi, TGFβi), FL6i (FGF2, LIF, P38i, JNKi, BMPi, GSK3βi, ERKi, TGFβi), AFTI (Activin A, FGF2, TGFβ1, Porcupine inhibitor IWP2), AFCI (Activin A, FGF2, CHIR99021, IWR-1), AFX (Activin A, FGF2, Tankyrase inhibitor XAV939), and AFCIW (Activin A, FGF2, CHIR99021, IWR-1, WH-4-023) systems (Choi et al., 2019; Gao et al., 2019). al., 2019; Kinoshita et al., 2021; Secher et al., 2017; Shi et al., 2020; Yoshimatsu et al., 2021; Yuan et al., 2019). The results of PCA analysis showed that PSCs in the 3i / LAF system had similarities with AFCIW-PSCs, AFCI-ESCs, AFX-EDSCs, and AFTI-iPSCs on PC1. Spearman correlation coefficient analysis further proved the similarity of these cell lines at the overall transcriptome level, but there were also differences between 3i / LAF-PSCs and these similar cell lines. Further analysis found that compared with other PSCs, 3i / LAF-PSCs had higher expression levels of epiblast characteristic genes, while lower expression levels of hypoblast and trophectoderm (TE) genes ( Figure 6 G).
[0362] Example 7: Application of iPSC reprogramming technology in cloned pig embryos
[0363] 7.1 Establishment of iPSCs line without exogenous gene integration in Wujin Huomao pig
[0364] This study used 10-year-old fire hair sow ear fibroblasts as the induction starting cells. The Wujin fire hair pig ear fibroblasts (Wujin-pEFs) have clear edges and can maintain a good proliferation state ( Figure 7A, 7B). Since adult fibroblasts have a higher degree of differentiation, this study added p-EV-pigLin28A and p-EV-pig NANOG to the above-mentioned episomal vector to optimize the induction process of Wujin-epi-iPSCs. Four days after electroporation of the episomal vector, the cells began to undergo MET, and a large number of epithelial-like cell colonies appeared. On the 20th day of induction, stem cell clones with smooth edges and raised morphology were observed in the induction wells ( Figure 7 C). The clones with good morphology were selected for expansion and culture, and an iPSCs line with dome-like morphology, smooth edges, and AP staining positive was successfully established ( Figure 7 D, 7E). The results of genomic PCR detection showed that the obtained Wujin-epi-iPSCs had no integration of exogenous gene vector fragments ( Figure 7 F). Immunofluorescence staining and qPCR results showed that Wujin-epi-iPSCs can express core pluripotency genes ( Figure 7 G, 7H). The karyotype of the cell line was detected and it showed a normal karyotype of 38 chromosomes ( Figure 7 I). The above results indicate that iPSCs with no exogenous integration and basic pluripotency characteristics were obtained from adult fibroblasts of Wujin Huomao pigs.
[0365] 7.2 iPSCs-derived cloned embryo development ability test
[0366] Studies have shown that the efficiency of cloned embryo development is highest when the diameter of the donor cells is between 15μm and 25μm. Since stem cells are small in size, this study used the method of differentiating stem cells into fibers to increase the cell volume in order to improve the efficiency of cloned embryo development. 24 hours after cell passage, the 3i / LAF medium was replaced with a system containing FGF2, BMP4, and SB431542. The cells gradually developed a flat morphology. After the cells were fully grown, they were passaged and supplemented with 1 / 2PEF medium for continuous culture. After 4 passages, the cells were able to stably form fibrous cells. Using the fibrous state cells as nuclear transplant donor cells, wild-type cells were able to develop into morphologically normal blastocysts ( Figure 7 J). The embryonic development was statistically analyzed, and the wild-type cell cleavage rate was 77.6±4.46%, and the blastocyst development rate was 18.61±0.28% ( Figure 7 K). The above results indicate that wild-type Wujinhuomao iPSCs have in vivo developmental potential and can be used as donor cells for nuclear transplantation.
[0367] Example 8: Role of FGF2 and LIF in the establishment of exogenous gene-independent iPSCs
[0368] In order to analyze the key signaling pathways of pig-specific exogenous gene-independent iPSCs establishment, this study conducted a comparative analysis of the transcriptomes of pig exogenous gene-independent iPSCs (3i / LAF-iPSCs, AFI-iPSCs, and AFCI-iPSCs) and exogenous gene-dependent iPSCs (LCDMV-iPSCs and FL3i-iPSCs). The results of Spearman correlation analysis showed that there were significant differences in the overall gene expression levels between exogenous gene-dependent iPSCs and exogenous gene-independent iPSCs. 3i / LAF-iPSCs are closer to AFTI-iPSCs and farther away from ALCIW-iPSCs ( Figure 8 A). All iPSCs expressed the pluripotency genes OTX2, SALL2, ZIC2, ZIC5, CDH1, DNMT3A, LIN28A, LIN28B, DNMT3B, and CLDN6, while LEFTY2, ZSCAN10, UTF1, NANOG, ETV4, ETV5, ESRP1, ZFP42, and PRDM14 were only highly expressed in iPSCs that were independent of exogenous genes, but not in iPSCs that were dependent on exogenous genes ( Figure 8 B). These genes specifically expressed in exogenous gene-independent iPSCs may be key factors in establishing the endogenous pluripotency regulatory network. In addition, OCT4, SOX2, and C-MYC were all expressed at high levels in exogenous gene-independent iPSCs, indicating that exogenous gene-independent iPSCs can activate the endogenous core pluripotency gene regulatory network. The above results show that there are significant differences in the gene expression patterns between exogenous gene-dependent iPSCs and exogenous gene-independent iPSCs, and the expression level of pluripotency genes in exogenous gene-independent iPSCs is higher.
[0369] This study used K-means cluster analysis to further analyze the differences in pluripotency regulatory signaling pathways between exogenous gene-dependent iPSCs and exogenous gene-independent iPSCs. Based on the differences in gene expression levels in exogenous gene-dependent iPSCs and exogenous gene-independent iPSCs, all genes were divided into 15 Clusters. Among them, Cluster_4 (C_4), Cluster_8 (C_8) and Cluster_14 (C_14) have different expression trends in exogenous gene-dependent and -independent iPSCs. C_4 and C_14 have high expression levels in exogenous gene-dependent iPSCs and low expression levels in exogenous gene-independent iPSCs; C_8 has low expression levels in exogenous gene-dependent cell lines and high expression levels in exogenous gene-independent cell lines ( Figure 8C). In order to clarify the specific signal regulation pathway of exogenous genes independent of iPSCs, functional enrichment analysis was performed on the genes contained in C_4&C_14 and C_8. The functional enrichment results showed that the cell lines independent of exogenous genes upregulated the ERK1 / 2 and LIF response signal pathways ( Figure 8 D). The above results indicate that activation of ERK1 / 2 signaling pathway and LIF signaling pathway may be the key signals for establishing exogenous gene-independent cell lines.
[0370] FGF2 is an activator of the MAPK / ERK signaling pathway, LIF is an activator of the LIF response signal, and IWR-1 is an inhibitor of the WNT signaling pathway. In order to clarify the key signaling pathways, this study removed FGF2, LIF or IWR-1 from the 3i / LAF system to form a reduced factor culture system for reprogramming, in order to analyze its effects on exogenous gene-independent iPSCs reprogramming.
[0371] Since GNT-pEFs can directly present the expression of the endogenous pluripotency gene NANOG, which is convenient for analyzing the reprogramming status, GNT-pEFs were used as the starting cells for factor-reduced reprogramming. First, the functions of growth factors FGF2 and LIF were analyzed. When reprogramming was performed using a system without FGF2, only a few clones were generated on the 18th day of induction ( Figure 8 E, 8F). Previous studies have shown that FGF2 can promote fibroblast proliferation and promote the reprogramming process. In the system without FGF2, 12 days after virus infection, fibroblasts showed poor proliferation; 18 days after virus infection, although NANOG-tdTomato positive clones were present in the induced wells, the clones were relatively loose and could not be established after picking ( Figure 8 G, 8H). Therefore, FGF2 may interfere with the reprogramming process by inhibiting the proliferation of early reprogramming cells. After LIF withdrawal, the number of induced clones decreased significantly, indicating that LIF is involved in the establishment of reprogramming ( Figure 8E, 8F). LIF can activate downstream signaling pathways by phosphorylating STAT3. Immunoblotting results showed that the level of phosphorylated STAT3 in iPSCs without LIF system was lower, indicating that LIF may promote the establishment of pluripotency during reprogramming by phosphorylating STAT3. qPCR detection results showed that iPSCs established under the withdrawal of LIF system can still silence exogenous genes. iPSCs established by reprogramming in the culture system composed of FGF2 and LIF are still dependent on exogenous genes (Fujishiro et al., 2013; Wang et al., 2013). The above results show that FGF2 and LIF can promote reprogramming, but they are not the key signaling pathways that mediate the acquisition of exogenous gene-independent iPSCs.
[0372] Example 9: Effect of WNT signaling pathway inhibition in exogenous gene-independent iPSCs establishment
[0373] Based on the functional enrichment results in Example 8, it was found that the exogenous gene-independent cell line downregulated the activity of the WNT signaling pathway ( Fig. 9 A). Genes related to the WNT signaling pathway are at a lower expression level in iPSCs that are independent of exogenous genes ( Fig. 9 B). The above results indicate that inhibition of the WNT pathway may be a key signal for establishing exogenous gene-independent cell lines.
[0374] IWR-1 can mediate the stabilization of the β-catenin degradation complex by interacting with Axin, thereby inhibiting the activity of the WNT / β-catenin pathway. This study used a system without IWR-1 for reprogramming to verify the role of WNT signaling pathway inhibition in the establishment of exogenous gene-independent iPSCs. On the 18th day of viral infection, NANOG-tdTomato-positive clones could be observed, but the clones formed were monolayered and flat ( Fig. 9 C). On the 20th day of induction, AP staining was performed on the induced wells. The results showed that the clone AP formed by the removal of IWR-1 was weakly positive ( Fig. 9 D). During the process of amplification and culture after picking, NANOG-tdTomato positive clones showed a fibrous differentiation morphology and heterogeneously expressed NANOG, and ultimately failed to form a stable cell line ( Fig. 9 F). In order to further clarify the effect of IWR-1 withdrawal on the reprogramming process, this study collected cells on the 15th day after virus infection and detected the expression of pluripotency genes. The results of qPCR detection showed that although endogenous OCT4 and NANOG could be activated, the expression of SOX2 was significantly reduced ( Fig. 9E). The active expression of the WNT signaling pathway can promote the development of the mesendoderm. The qPCR test results showed that the expression levels of mesendoderm development-related genes BMP4, EOMES and TBXT were significantly upregulated after the withdrawal of IWR-1 ( Fig. 9 E). Down-regulation of SOX2 expression and up-regulation of mesendoderm gene expression indicate that withdrawal of IWR-1 enables the reprogrammed cells to have the characteristics of mesendoderm differentiation, similar to the primitive streak stage of the early differentiation process. Inhibition of the WNT signaling pathway during the maturation stage of human iPSCs reprogramming can avoid mesendoderm differentiation. Although withdrawal of Activin A and CHIR99021 reduced the reprogramming efficiency, it was also possible to obtain iPSCs with exogenous gene silencing, AP staining positive, and endogenous NANOG activation ( Fig. 9 H, 9I). WH-4-023 did not affect the reprogramming efficiency, but the iPSCs obtained were flat ( Fig. 9 G, 9H), and exogenous gene-independent iPSCs can still be obtained under the WH-4-023 system. Therefore, although Activin A, CHIR99021 and WH-4-023 are involved in the establishment of high-quality reprogramming systems, they are not the key signaling pathways that mediate the establishment of exogenous gene-independent iPSCs. In short, IWR-1 may be a key signaling molecule that mediates the establishment of exogenous gene-independent iPSCs.
[0375] Example 10: Comparison of cell line establishment under different culture systems
[0376] This study combined the different recently reported porcine stem cell culture systems and compared their reprogramming conditions (Choi et al., 2019; Gao et al., 2019; Xu et al., 2019; Zhang et al., 2014). A small number of NANOG-tdTomato-positive clones were induced in the ALCIW system, but the clones were not successfully established due to unstable proliferation; no NANOG-tdTomato-positive clones were obtained in the FL6i system, and no further establishment was performed; while NANOG-tdTomato-positive iPSCs lines were obtained in the 3i / LAF, AFI, AFCI, LCDMV and FL3i (FGF2, LIF, MEKi, GSK3β, TGFβ) systems. These cell lines were tested for exogenous gene silencing, and the results showed that NANOG-tdTomato-positive iPSCs obtained in systems containing WNT inhibitors (such as 3i / LAF, AFI, and AFCI) could silence exogenous genes, while NANOG-tdTomato-positive iPSCs in systems without WNT inhibitors (such as LCDMV and FL3i) could not silence exogenous genes ( Fig.10 A). The qPCR detection results of endogenous pluripotency genes OCT4, NANOG and SOX2 showed that the established iPSCs lines can express SOX2 and NANOG, but OCT4 is only expressed in iPSCs that are independent of exogenous genes. It can be seen that the silencing of exogenous genes corresponds to the activation of OCT4 expression, which is consistent with the previous report in mice that exogenous gene silencing can promote the activation of endogenous OCT4 expression (Li et al., 2011) ( Fig.10 B). GSK3β inhibitor CHIR99021 can activate the WNT signaling pathway when acting alone (An et al., 2010). The 3i / LAF-iPSCs and AFCI-iPSCs systems contain not only the WNT inhibitor IWR-1, but also the WNT activator CHIR99021. Previous studies have shown that IWR-1 and CHIR99021 can synergistically mediate the localization of β-catenin in the cytoplasm to maintain a stable stem cell state (Kim et al., 2013). This study analyzed the stem cell WNT signaling pathway under the 3i / LAF and AFCI systems by Gene Set Enrichment Analysis (GSEA) to further clarify the activity of the WNT signaling pathway. The results showed that the WNT signaling pathway was in an inhibited state in both 3i / LAF-iPSCs and AFCI-ESCs (Choi et al., 2019). β-catenin nuclear entry is the key to activate the classic WNT signaling pathway (Clevers and Nusse, 2012). β-catenin staining results showed that β-catenin did not enter the nucleus in 3i / LAF-iPSCs. qPCR detection results showed that the expression levels of WNT pathway-related genes in exogenous gene-independent iPSCs (3i / LAF-iPSCs, AFCI-iPSCs, AFI-iPSCs) were lower than those in exogenous gene-dependent iPSCs (FL3i-iPSCs, LCDMV-iPSCs). The above results further verified the key role of WNT inhibition in the establishment of exogenous gene-independent iPSCs.
[0377] The non-receptor tyrosine kinase SRC participates in the regulation of embryonic development and cell growth by regulating EMT transformation. WH-4-023 is an inhibitor of SRC. Reprogramming was performed in a system without WH-4-023. On the 18th day of induction, the clones in the induced wells expressed NANOG fluorescence, but showed a flat morphology ( Fig.10F). NANOG-tdTomato positive clones were selected for line establishment, and the iPSCs lines established were also flat and positive for AP staining. After WH-4-023 was added again to the iPSCs established after WH-4-023 was removed, the flat cells were able to recover to a convex morphology within two generations ( Fig.10 G), it can be seen that the effect of WH-4-023 withdrawal on cell morphology is reversible. qPCR detection showed that after the withdrawal of WH-4-023, the expression of EMT-related genes such as SRC, BMP2, BMP4, WNT8A, EOMES, KRT8, SPARC and EPHA2 increased ( Fig.10 I). Therefore, WH-4-023 maintains cell protrusion morphology by inhibiting EMT.
[0378] A stable and efficient reprogramming system can shorten the induction process of iPSCs. Previous research results have shown that inhibiting WNT is necessary for the establishment of exogenous gene-independent iPSCs. On this basis, the identification of a stable and efficient reprogramming system is still a problem that needs to be further clarified. The number of NANOG-tdTomato positive clones in each system on the 18th day of induction was counted, and the results showed that the 3i / LAF system induced the largest number of NANOG-tdTomato positive clones ( Fig.10 J). As many NANOG-tdTomato positive clones as possible were selected from each system for system establishment. The results showed that the establishment efficiency of the AFI system was 23.08%, AFCI was 4.00%, ALCIW was 0.00%, and the establishment efficiency of the 3i / LAF system reached 78.57%, which was significantly higher than that of other groups. Although the established 3i / LAF-iPSCs, AFCI-iPSCs and AFI-iPSCs were able to show NANOG-tdTomato fluorescence, only 3i / LAF-iPSCs showed a convex morphology ( Fig.10 E). Expression of three germ layer differentiation genes was detected, and the results showed that the expression of PAX6, TBXT and SOX17 in 3i / LAF-iPSCs was significantly lower than that in AFCI-iPSCs and AFI-iPSCs ( Fig.10 H). In conclusion, the 3i / LAF system is an efficient porcine iPSCs establishment system that does not rely on exogenous genes.
[0379] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes may be made to the details according to all the teachings that have been published, and these changes are within the scope of protection of the present invention. The entire invention is given by the attached claims and any equivalents thereof.
[0380] References:
[0381] Xu,J.,Yu,L.,Guo,J.,Xiang,J.,Zheng,Z.,Gao,D.,Shi,B.,Hao,H.,Jiao,D.,Zhong,L.,et al.(2019).Generation of pig induced pluripotent stem cells usingan extended pluripotent stem cell culture system.Stem Cell Res.Ther.10,193.
[0382] Zhi,M.,Zhang,J.,Tang,Q.,Yu,D.,Gao,S.,Gao,D.,Liu,P.,Guo,J.,Hai,T.,Gao,J.,et al.(2021).Generation and characterization of stable pig pregastrulationepiblast stem cell lines.Cell Res.32,383-400.
[0383] Gao,X.,Nowak-Imialek,M.,Chen,X.,Chen,D.,Herrmann,D.,Ruan,D.,Chen,A.C.H.,Eckersley-Maslin,M.A.,Ahmad,S.,Lee,Y.L.,et al.(2019).Establishment ofporcine and human expanded potential stem cells.Nat.Cell Biol.21,687-699.
[0384] Choi,K.H.,Lee,D.K.,Kim,S.W.,Woo,S.H.,Kim,D.Y.,and Lee,C.K.(2019).Chemically Defined Media Can Maintain Pig Pluripotency Network In Vitro.StemCell Rep.13,221-234.
[0385] Yuan,Y.,Park,J.,Tian,Y.,Choi,J.,Pasquariello,R.,Alexenko,A.P.,Dai,A.,Behura,S.K.,Roberts,R.M.,and Ezashi,T.(2019).A six-inhibitor culture mediumfor improving -type pluripotency of porcine pluripotent stem cells.CellDeath Discov.5,104.
[0386] Shi,B.,Gao,D.,Zhong,L.,Zhi,M.,Weng,X.,Xu,J.,Li,J.,Du,X.,Xin,Y.,Gao,J.,et al.(2020).IRF-1 expressed in the inner cell mass of the porcine earlyblastocyst enhances the pluripotency of induced pluripotent stem cells.StemCell Res.Ther.11,505.
[0387] Secher,J.O.,Ceylan,A.,Mazzoni,G.,Mashayekhi,K.,Li,T.,Muenthaisong,S.,Nielsen,T.T.,Li,D.,Li,S.,Petkov,S.,et al.(2017).Systematic in vitro and invivo characterization of Leukemia-inhibiting factor-and Fibroblast growthfactor-derived porcine induced pluripotent stem cells.Mol.Reprod.Dev.84,229-245.
[0388] Mao, J., Zhang, Q., Deng, W., Wang, H., Liu, K., Fu, H., Zhao, Q., Wang, X., and Liu, L.(2017).Epigenetic Modifiers Facilitate Induction and Pluripotency ofPorcine iPSCs.Stem Cell Rep.8,11-20.
[0389] Kinoshita, M., Kobayashi, T., Planells, B., Klisch, D., Spindlow, D., Masaki, H., Bornelov, S., Stirparo, GG, Matsunari, H., Uchikura, A., et al livestock species.Development 148,dev199901.
[0390] Yoshimatsu, S., Nakajima, M., Iguchi, A., Sanosaka, T., Sato, T., Nakamura, M., Nakajima, R., Arai, E., Ishikawa, M., Imaizumi, K., et al MammalianSpecies.Stem Cell Rep.16,754-770.
[0391] Han , J. , Yuan , P. , Yang , H. , Zhang , J. , Soh , BS , Li , P. , Lim , SL , Cao , S. , Tay , J. , Orlov , Y. L. , et al.
[0392] Wen,W.,Zhang,J.P.,Xu,J.,Su,R.J.,Neises,A.,Ji,G.Z.,Yuan,W.,Cheng,T.,and Zhang,X.B.(2016).Enhanced Generation of Integration-free iPSCs from HumanAdult Peripheral Blood Mononuclear Cells with an Optimal Combination ofEpisomal Vectors.Stem Cell Rep.6,873-884.
[0393] Schlaeger,T.M.,Daheron,L.,Brickler,T.R.,Entwisle,S.,Chan,K.,Cianci,A.,DeVine,A.,Ettenger,A.,Fitzgerald,K.,Godfrey,M.,et al.(2015).A comparisonof non-integrating reprogramming methods.Nat.Biotechnol.33,58-63.
[0394] Fujishiro,S.H.,Nakano,K.,Mizukami,Y.,Azami,T.,Arai,Y.,Matsunari,H.,Ishino,R.,Nishimura,T.,Watanabe,M.,Abe,T.,et al.(2013).Generation of naive-like porcine-induced pluripotent stem cells capable of contributing toembryonic and fetal development.Stem Cells Dev.22,473-482.
[0395] Wang,J.,Gu,Q.,Hao,J.,Jia,Y.,Xue,B.,Jin,H.,Ma,J.,Wei,R.,Hai,T.,Kong,Q.,et al.(2013).Tbx3 and Nr5α2 play important roles in pig pluripotent stemcells.Stem Cell Rev.9,700-708.
[0396] Zhang,Y.,Wei,C.,Zhang,P.,Li,X.,Liu,T.,Pu,Y.,Li,Y.,Cao,Z.,Cao,H.,Liu,Y.,et al.(2014).Efficient reprogramming of -like induced pluripotent stemcells from porcine adipose-derived stem cells with a feeder-independent andserum-free system.PloS One 9,e85089.
[0397] Li,Y.,Zhang,Q.,Yin,X.,Yang,W.,Du,Y.,Hou,P.,Ge,J.,Liu,C.,Zhang,W.,Zhang,X.,et al.(2011).Generation of iPSCs from mouse fibroblasts with asingle gene,Oct4,and small molecules.Cell Res.21,196-204.
[0398] An,W.F.,Germain,A.R.,Bishop,J.A.,Nag,P.P.,Metkar,S.,Ketterman,J.,Walk,M.,Weiwer,M.,Liu,X.,Patnaik,D.,et al.(2010).Discovery of Potent andHighly Selective Inhibitors of GSK3b.In Probe Reports from the NIH MolecularLibraries Program(Bethesda(MD):National Center for Biotechnology Information(US)).
[0399] Kim,H.,Wu,J.,Ye,S.,Tai,C.I.,Zhou,X.,Yan,H.,Li,P.,Pera,M.,and Ying,Q.L.(2013).Modulation of β-catenin function maintains mouse epiblast stemcell and human embryonic stem cell self-renewal.Nat.Commun.4,2403.
Claims
1. A method for producing induced pluripotent stem cells (iPSCs), the method comprising: (i) Reprogramming pig somatic cells; (ii) culturing the cells of step (i) in a medium comprising a WNT signaling pathway inhibitor, CHIR99021, a Src inhibitor, LIF, a TGF-β superfamily member, and a fibroblast growth factor to generate iPSCs.
2. The method of claim 1, wherein: The WNT signaling pathway inhibitor is IWR-1; The Src inhibitor is WH-4-023; The TGF-β superfamily member is Activin A; and / or, The fibroblast growth factor is FGF2.
3. The method according to any one of claims 1 to 2, wherein: The WNT signaling pathway inhibitor is IWR-1, and the content ratio of IWR-1 to CHIR99021 is 2:3-1:3, such as 1:2-1:
3.
4. The method according to any one of claims 1 to 3, which has one or more of the following features: (1) The content of the WNT signaling pathway inhibitor is 1-5 μM, for example, 1 μM, 2.5 μM, 3 μM, 5 μM; (2) The content of CHIR99021 is 0.01-3 μM, for example, 0.01 μM, 0.1 μM, 1 μM, 2 μM, 3 μM; (3) The content of the Src inhibitor is 0.01-5 μM, for example, 0.01 μM, 0.1 μM, 1 μM, 3 μM, 5 μM; (4) The content of LIF is 1-100 ng / mL, for example, 1 ng / mL, 10 ng / mL, 25 ng / mL, 50 ng / mL, 100 ng / mL; (5) The content of the TGF-β superfamily member is 1-100 ng / mL, for example, 1 ng / mL, 10 ng / mL, 25 ng / mL, 50 ng / mL, 100 ng / mL; (6) The content of the fibroblast growth factor is 1-100 ng / mL, for example, 1 ng / mL, 10 ng / mL, 25 ng / mL, 50 ng / mL, 100 ng / mL.
5. The method according to any one of claims 1 to 4, wherein The reprogramming comprises: introducing reprogramming factors into pig somatic cells; Preferably, the reprogramming factors include OCT4, SOX2, KLF4 and C-MYC; Preferably, the reprogramming factors include hOCT4, hSOX2, hKLF4, and hC-MYC; Preferably, the reprogramming factors further include BCL2L1 (eg, hBCL2L1); Preferably, the reprogramming factors include hOCT4, hSOX2, hKLF4, hC-MYC and hBCL2L1; Preferably, the reprogramming factors further include LIN28A (e.g., pLIN28A) and NANOG (e.g., pNANOG); Preferably, the reprogramming factors include hOCT4, hSOX2, hKLF4, hC-MYC, hBCL2L1, pLIN28A and pNANOG.
6. The method of claim 5, wherein: The reprogramming factors are encoded by one or more exogenous expression cassettes; Preferably, the one or more exogenous expression cassettes are contained in a non-integrating vector; Preferably, the non-integrative vector is an Episomal vector; Preferably, the non-integrating vector is a pEV vector comprising spleen focus forming virus promoter (SFFV), WPRE, OriP and EBNA1 elements; Preferably, the method further comprises: (iii) detecting the residual situation of the exogenous gene at the endogenous locus to screen cells without the exogenous gene residual at the endogenous locus; Preferably, the one or more exogenous expression cassettes are contained in an integrative vector; Preferably, the integrative vector is a retrovirus, a lentivirus or a transposase vector; Preferably, the method further comprises: (iii) detecting (eg, quantitative PCR) the expression of the exogenous gene to screen cells in which the exogenous gene is silenced.
7. The method according to any one of claims 1 to 6, wherein The culture medium in step (ii) further comprises a basal culture medium; Preferably, the basal medium is a basal medium for culturing mammalian (preferably pig) pluripotent stem cells; Preferably, the basal medium is a minimal medium supplemented with the following components: N2supplement, B27supplement, non-essential amino acids, β-mercaptoethanol, serum replacement (e.g., knockout serum replacement), and glutamine or its derivatives (e.g., GlutaMAX); Preferably, the basic culture medium is selected from DMEM / F12, Neurobasal, DMEM, KO-DMEM, RPMI1640, MEM, mTeSR1 or any combination thereof; Preferably, the basic culture medium is selected from DMEM / F12, Neurobasal or a combination thereof; Preferably, the basic culture medium is DMEM / F12 and Neurobasal.
8. The method according to any one of claims 1 to 7, wherein The culturing after the reprogramming factors are introduced into the somatic cells is performed in the presence of a feeder layer; Preferably, the feeder layer is mouse embryonic fibroblasts.
9. Use of a culture medium for preparing induced pluripotent stem cells (iPSCs), wherein: The culture medium is as defined in any one of claims 1 to 7; Preferably, the iPSC is an exogenous gene-independent porcine iPSC.
10. Induced pluripotent stem cells (iPSCs) produced by the method of any one of claims 1 to 9; Preferably, the iPSC expresses OCT4, SOX2, and NANOG; Preferably, the iPSCs also express KLF4, C-MYC, REX1, LIN28A, SALL4 and OTX2; Preferably, the iPSCs have the ability to differentiate into cells of any one of endoderm, ectoderm and mesoderm; Preferably, the iPSCs are capable of forming a domed shape clone morphology; Preferably, the iPSCs can be stably passaged for at least 50 times or more; Preferably, the iPSCs can be stably passaged for at least 100 times or more; Preferably, the iPSC is an exogenous gene-independent porcine iPSC.
11. A genetically modified iPSC obtained by genetically modifying the iPSC according to claim 10; Preferably, the genetic modification comprises genome editing, for example comprising nucleic acid fragment deletion, gene modification, gene knockout, alteration of gene product expression, repair of mutation, polynucleotide insertion, single base mutation or any combination thereof; Preferably, the genome editing comprises gene insertion, gene knock-in, gene knock-out, gene mutation (eg, single base mutation) or any combination thereof.
12. Use of the iPSC according to claim 10 or the genetically modified iPSC according to claim 11 for generating cells, tissues or organs (such as organoids) in vitro; Preferably, the cells include cells of endoderm, ectoderm or mesoderm; Preferably, the cells are selected from immune cells, dopaminergic neural precursor cells, cardiomyocytes, β cells, eye-specific cells, muscle cells, fat cells, and bone cells; preferably, the organoids are selected from intestinal organoids, kidney organoids, liver organoids, brain organoids, alveolar organoids, gastric organoids, etc.
13. A method for producing cells, tissues or organs (e.g., organoids) in vitro, comprising: Cultivating the iPSC according to claim 10 or the genetically modified iPSC according to claim 11 under conditions that induce differentiation; Preferably, the cells include cells of endoderm, ectoderm or mesoderm; Preferably, the cells are selected from immune cells, dopaminergic neural precursor cells, cardiomyocytes, β cells, eye-specific cells, muscle cells, fat cells, and bone cells; preferably, the organoids are selected from intestinal organoids, kidney organoids, liver organoids, brain organoids, alveolar organoids, gastric organoids, etc.
14. Use of the iPSC according to claim 10 or the genetically modified iPSC according to claim 11 for preparing cultured meat; Preferably, the iPSCs or genetically modified iPSCs are used as seed cells.
15. A method for preparing cultured meat, comprising: (1) Providing the iPSC according to claim 10 or the genetically modified iPSC according to claim 11; (2) Inducing the iPSCs described in step (1) to differentiate into muscle cells to obtain cultured meat.
16. A method for producing a porcine embryo, the method comprising: Creating an embryo by a nuclear transfer process, wherein the nucleus of the iPSC of claim 10 or the genetically modified iPSC of claim 11 is transplanted into an enucleated porcine oocyte or egg cell; Preferably, before performing nuclear transplantation, the method further comprises culturing the nuclear donor cell under differentiation-inducing conditions; Preferably, the method comprises forming fibrous cells as nuclear donor cells under differentiation-inducing conditions of FGF2, BMP4 and SB431542; Preferably, the method comprises: generating the iPSC from pig somatic cells using the method according to any one of claims 1 to 8, or generating iPSC from pig somatic cells using the method according to any one of claims 1 to 8 and genetically modifying the iPSC to generate the genetically modified iPSC; Preferably, the iPSCs or genetically modified iPSCs are derived from somatic cells of a rare or endangered pig breed.
17. Use of the iPSC according to claim 10 or the genetically modified iPSC according to claim 11 for generating pig embryos; Preferably, the iPSCs or genetically modified iPSCs are derived from somatic cells of a rare or endangered pig breed.
18. Use of an agent capable of inhibiting the WNT signaling pathway for preparing exogenous gene-independent pig iPSCs; Preferably, the reagent comprises a WNT signaling pathway inhibitor and CHIR99021; Preferably, the WNT signaling pathway inhibitor is IWR-1; Preferably, the reagent comprises IWR-1 and CHIR99021; Preferably, the WNT signaling pathway inhibitor is IWR-1, and the content ratio of IWR-1 to CHIR99021 is 2:3-1:3, such as 1:2-1:
3.
19. Use of LIF for improving the reprogramming efficiency of exogenous gene-independent porcine iPSCs.
20. Use of a SRC inhibitor for maintaining the dome-shaped clonal morphology of exogenous gene-independent porcine iPSCs.
Citation Information
Cited By
Primer probe composition for detecting iPSC residues in iPSC-derived mesenchymal stem cells and application of primer probe composition
CN121759613A
Product, system and method of cell cultivation
US12668774B2
Culture media based on protein hydrolysate and a process for preparing thereof
US12686847B2
Pet food, methods and devices for producing pet food
US12772996B2
